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The therapeutic potential of peptides is limited by poor oral bioavailability due to their 
susceptibility to enzymatic degradation in the gastrointestinal tract and unfavourable 
physicochemical properties. Des- Asp angiotensin I (DAA-I) is an example of a physiological 
peptide which can be potentially used for the treatment of cardiovascular diseases (namely, the 
attenuation of post- infarction injuries and neointima growth in catheter- injured arteries). 
Although preliminary studies suggest that DAA-I is able to transverse the intestinal epithelium, 
the extent of transport and its transport route have not been investigated in detail. By 
systematically examining the transport properties of DAA-I across Caco-2 monolayers, this 
project serves to address these issues in greater detail.  
 
DAA-I is structurally related to angiotensin III (Ang III) and angiotensin IV (Ang IV). In 
this investigation, we are interested in comparing the transport properties of these structurally 
related peptides and examining how their transport would be affected by physicochemical 
properties (lipophilicity, hydrogen- bonding potential, charge) and structure (area, volume, 
conformation). 
 
The metabolic stability and the transport properties of these peptides were examined using 
the Caco-2 cell monolayers as a surrogate model for the intestinal epithelium. Lipophilicity was 
evaluated experimentally by reverse phase chromatography. The secondary structure of the 
peptides were investigated using circular dichroism and 1H-NMR and the data subsequently used 
together with a molecular modelling software to construct probable low energy conformation(s) of 
the peptide. Physicochemical properties like volume, polar surface area, hydrogen bonding 
potential, ClogP were obtained from these minimised conformations.  
 vi
The angiotensin peptides exhibited limited permeability (P app ≈ 10 -8 to 10 -9 cm/sec) 
across the Caco-2 cell monolayers. They were largely stable to enzymatic degradation in the 
presence of the Caco-2 cells.  Different routes of transport were observed for the peptides. The 
transport of DAA-I shows many characteristics of transcellular diffusion, in contrast to Ang IV 
which is transported by an energy-requiring pathway. More than one route is implicated for Ang 
III, depending on concentration of the peptide.   
 
Spectroscopic data and molecular modelling suggest the presence of secondary structures 
in Ang III and Ang IV, but not in DAA-I. Ang III appears to have more conformational options 
than Ang IV. As to whether the transport properties of the peptides are related to their 
physicochemical and structural characteristics, there is support from the present findings that 
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The oral delivery of peptides is hampered by their susceptibility to enzymatic degradation 
in the gastrointestinal tract and their hydrophilic characteristics that limit transport across the 
intestinal mucosa. 1 For these reasons, peptides have highly variable oral bioavailability, which 
seriously restricts their potential as therapeutic agents. Ironically, research in therapeutic peptides 
has not been restricted by this limitation. Rather, technological advances in peptide synthesis and 
the development of combinatorial peptide libraries have sustained interest in this area of research 
with encouraging outcomes, as seen from the availability of chemically modified analogues of 
physiological peptides, many of which have greater biological activity and superior 
pharmacokinetic profiles than the original peptide. 2 The synthetic peptide analogues of 
gonadotropin- releasing hormone such as buserelin and gonadorelin, are cases in point. 3 Novel 
peptide- like compounds (peptidomimetics) with a wide range of pharmacological activity (HIV 
protease inhibitors, renin inhibitors, glycoprotein IIb/IIIa antagonists) have also been reported. 4 
There is also a growing interest in peptides derived from the hydrolysis of dietary proteins. Most 
of these are oligopeptides (peptides consisting of 2 to 12 amino acids). Besides fulfilling a 
nutritional role, many of these peptides are reported to possess “functional” effects such as opiate- 
like, hypotensive, immunomodulatory and anti-coagulative properties. 5 Oligopeptides that can 
lower the blood pressure of spontaneous hypertensive rats 6 and moderate the release of insulin 7 
and somatostatin 8 in dogs have been reported in the literature. 
 
 The therapeutic potential of peptides – whether derived from rational design or occurring 
fortuitously in food substances – is limited by their poor intestinal absorption. This problem may 
be overcome by several approaches, like structural modifications to increase stability against 
enzymatic degradation, and the use of delivery systems to optimise oral delivery. There is a 
growing awareness that the structural features of a peptide will determine its physicochemical 
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characteristics, which will in turn influence the extent to which it can transverse the intestinal 
epithelial barrier. Thus a better understanding of the interplay between these factors is likely to 
yield effective solutions to the problems associated with peptide bioavailability. 
   
1.1 Transport of Oligopeptides Across the Intestinal Epithelium  
 
Figure 1 is a diagrammatic representation of the barriers encountered by a solute as it 
moves from the intestinal lumen to the portal circulation. The solute must transverse the mucus 
coat and associated unstirred water layer overlying the layer of epithelial cells comprising the 
intestinal epithelium. The latter consists mainly of absorptive enterocytes, mucus secreting goblet 
cells, enteroendocrine cells and Paneth cells. Underlying the epithelial cells is the basement 
membrane. To gain access to the mesenteric circulation, the solute must cross the basement 
membrane, interstitial space and finally the capillary endothelium. 
 






















a. Intestinal lumen. 
b. Mucus. 
c. Enterocytes. 
d. Basement membrane. 
e. Interstitium. 
f. Capillary. 
g. Paracellular route. 
h. Transcellular route. 
 
The various routes and mechanisms of transfer across the intestinal epithelium are well 
described. 9 Table 1 summarises some of the salient features of the mechanisms underlying the 
transport routes across the epithelium. The transport of a solute across the intestinal epithelium is 
determined by the physicochemical characteristics of both the solute and the cellular barrier. In 
addition, more than one process may contribute to the overall absorption of a given solute. 
 
Table 1: Mechanisms of transport across epithelial barriers. 
 
Mechanism                           Characteristics 



















Energy independent.  
Flux down a concentration gradient (based on Fick’s 1st Law of diffusion) 
 
Energy independent  
Flux down a concentration gradient 
Flux is saturable at high concentrations.  
Carrier mediated (substrate specific)  
Susceptible to competing substrates and inhibitors.  
 
Energy dependent 
Flux against a concentration gradient 
Substrate specificity, competition and saturation. 
 
Usually energy dependent. 











c) Fluid phase/ pinocytosis 
 
Substrate specificity, saturable. 
Usually high affinity but low capacity. 
 
Non-specific adsorption 
Competition and saturation. 
High capacity. 
 




 These mechanisms of transport apply to both peptidic and non- peptidic solutes. A 
preference for certain transport routes have been noted for oligopeptides. These are active 
transport mediated by the PepT1 transporter, transcytosis and paracellular transport through 
intercellular junctions for suitably sized solutes. 
 
    A review of the literature shows that various pathways are described for the transport of 
oligopeptides across the Caco-2 monolayer. A summary is presented in the following paragraphs. 
 
1.1.1 Paracellular transport of oligopeptides 
 
 The paracellular route is an aqueous pathway involving the passive diffusion of the solute 
along the extracellular space between adjacent epithelial cells. Passage is regulated by the tight 
junctions between cells and only “small” hydrophilic solutes can filter through the water- filled 
pores of the tight junction. 10   The general consensus is that only oligopeptides with six and fewer 
amino acids will be transported by this route. Since the electric field at the junctional complex is 
negatively charged, positively charged solutes are preferentially transported. It is noted that the 
radius of the pores varies along the gastrointestinal tract, being larger in the jejunum and 
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decreasing down the ileum and colon. There is a corresponding decrease in number of pores as 
well. This means that paracellular transport of solutes is likely to occur in the upper (rather than 
the lower) part of the gastrointestinal (GI) tract.  
 
 Pauletti and coworkers evaluated the relative importance of size and charge on the passive 
diffusion of metabolically stable capped amino acids, tripeptides and hexapeptides which were 
either neutral or positively/ negatively charged. 11 They showed that the anticipated charge 
selectivity (i.e. positive > negative) is only observed for the small sized capped amino acids. With 
the larger tripeptides and hexapeptides, charge considerations are overshadowed by size factors.   
 
 The importance of lipophilicity, polar surface area and hydrogen bonding capacity to the 
paracellular transport of oligopeptides was investigated by Werner et al, using a series of 
oligopeptides (3- 4 amino acids in length) that are related to thyrotropin releasing hormone. 12 Not 
unexpectedly, these physicochemical properties are not found to influence the apparent 
permeability coefficients (Papp) of the peptides. In fact, the presence of a correlation would suggest 
the operation of a different transport route (possibly, transcellular) for these peptides. 
 
 The paracellular route was proposed for the transport of the opiate peptide met-enkephalin 
(Tyr-Gly-Gly-Phe-Met) and 3 of its metabolically stabilised analogues (D-Ala2 met-enkephalin, 
D-Ala2 met-enkephalin amide, metkephamide) across the Caco-2 monolayer based on the 
following observations. 13 First, the peptides were found to have effective permeability 
coefficients (Peff  ≈ 10 -8 cm/sec) that are typical of paracellular markers. Secondly, it was observed 
that the transport of metkephamide was significantly increased in the presence of EDTA. EDTA 
depletes Ca2+ at the tight junctions, leading to the opening of the intercellular spaces and greater 
access across the tight junction. Thirdly, visualisation of the permeation pathway of a fluorophore- 
labeled analogue of metkephamide by confocal laser scanning microscopy showed that the 
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labelled peptide was located exclusively in the intercellular space. In addition, there was no 
correlation between permeability and apparent partition coefficient values of the peptides, as 
would be expected for paracellular transport. 
 
 Satake and coworkers described the transport of Val-Pro-Pro, an inhibitor of angiotensin 
converting enzyme (ACE) isolated from fermented milk, across the Caco-2 monolayer. 14 The flux 
of Val-Pro-Pro was not saturable and not inhibited by known inhibitors of the peptide transporter 
PepT1. In addition, the apical- to- basolateral flux of Val-Pro-Pro was not inhibited by endocytosis 
inhibitors, wortmannin and phenylarsine oxide. Since the transcytotic process is initiated by 
endocytosis at the apical membrane, it was concluded that the transepithelial transport of Val-Pro-
Pro is not mediated by transcytosis. Based on these exclusion criteria, paracellular diffusion is 
likely to be the main mechanism for the transport of intact Val-Pro-Pro. The authors proposed that 
the amount of Val-Pro-Pro actually absorbed during food intake is higher than that predicted from 
in vitro transport experiments using Caco-2. This is because the paracellular permeability of Caco-
2 cells is more closely aligned to permeation across the colon rather than the ileum in rats. 15 This 
would imply that for solutes that are transported by the paracellular route, their rates of permeation 
are likely to be underestimated by the Caco-2 model.   
 
1.1.2 Transcellular transport of oligopeptides 
 
 The transcellular pathway involves movement of the solute through the apical plasma 
membrane, across the cytosol and finally transversing the basolateral membrane by either an 
active or passive process.  Transcellular movement of solutes by passive diffusion is more widely 
encountered, which is understandable as active transport is restricted to substrate- specific carrier- 
mediated processes.    
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The diffusion of a solute across a cell membrane is determined by the balance of water- 
solute and membrane- solute forces. For lipophilic solutes, water- solute interactions are minimal 
and the main impetus driving the transfer of the solute from the aqueous phase into the membrane 
interior is the hydrophobic effect. In contrast, a polar solute like a peptide is extensively hydrated 
in water and would require energy to desolvate (remove) the shell of water molecules surrounding 
it before it can diffuse across the cell membrane.   
 
 Burton and coworkers investigated the lipophilicity and hydrogen bonding potential of a 
homologous series of phenylalanine-containing oligopeptides. 16 In their investigations, 
lipophilicity was evaluated from partition coefficients in octanol/ buffer and isooctane/ buffer. The 
octanol partition coefficient was proposed to represent the affinity of the peptide for the hydrated 
polar head group region of the phospholipid bilayer, an important region of the membrane that 
separates the aqueous phase from the apolar membrane interior. The partitioning of the peptide 
into this interface is driven by the hydrophobic effect (about 70 % of the hydrophobic force 
associated with the peptide is expended as it moves from the aqueous phase into this region) as 
well as the extent of hydrogen bonding between the peptide and the polar head groups in the 
interface. The hydrogen bonding potential of a peptide was assessed by two methods: the 
difference in partition coefficients determined in octanol and a lipophilic solvent (in this case, 
isooctane) [∆ log PC = log PC octanol – log PC isooctane] and the partition coefficient in octanol/ 
ethylene glycol (log PC octanol/ glycol). A peptide with strong hydrogen bonding potential will have 
numerically large  ∆ log PC and/ or log PC octanol/ glycol values, implying that the desolvation energy 
of this peptide (i.e. energy required to break hydrogen bonds) is considerable. Such a peptide will 
be preferentially localised in the interface and will not partition into the hydrophobic membrane 
interior to a significant extent. It is likely to have poor permeability characteristics. In other words, 
for a peptide to efficiently cross the cell membrane, it must have an affinity for the interface (large 
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octanol partition coefficient) as well as a small desolvation energy (small ∆ log PC or log PC octanol/ 
glycol).   
 
 The role of partition coefficient determinations as predictors of membrane permeability is 
discussed by Goodwin and coworkers using a series of dipeptide mimetics. 17, 18  They found that 
the permeability of these peptides across a Caco-2 monolayer is better correlated to log PC heptane/ 
glycol rather than log PC octanol  or the ∆log PC parameter (where ∆ log PC = log PC octanol – log PC 
heptane].  They proposed that log PC octanol reflects the volume (or surface area) and hydrogen bond 
acceptor potential of the solute, while ∆ log PC reflects the hydrogen bond donor capacity of the 
solute. In contrast, log PC heptane/ glycol combines characteristics of both log PC octanol and ∆log PC 
and thus reflects hydrogen bonding potential and volume characteristics of the solute. This 
explains its qualitatively good correlation to permeability. From the membrane point of view, 
heptane mimics the non-polar interior of the cell membrane while ethylene glycol resembles the 
glycerol ester region of the membrane-water interface. 19 Since the microenvironment of the 
bilayer is comprehensively described by the solvent properties of heptane and ethylene glycol, log 
PC heptane/ glycol is expected to be a good predictive of cell permeability. 
 
  The results of Goodwin et al also emphasise the importance of hydrogen bond donor 
groups in the solute for good membrane permeability. 17, 18 They cited an example in which two 
solutes, an amide 1 and an amine 2 were compared. Both have comparable log PC octanol values, 
suggesting similar hydrogen bond acceptor potentials. ∆log PC of 1 (5.99) is greater than that of 2 
(4.23), which means that 1 has greater H bond donor potential than 2. Amine 2 has greater 
permeability than amide 1 when evaluated in the Caco-2 cell model. Thus, changing the amide to 
the amine results in a “beneficial” loss of hydrogen bond donor capacity (while maintaining a 
similar level of hydrogen bond acceptor ability) which in turn leads to greater permeability. 
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Clearly, improvement in permeability can be achieved more effectively by changing hydrogen 
bonding potential of the solute than by altering its lipophilicity (for example, by extending 
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 The importance of solute properties such as lipophilicity, hydrogen bonding potential and 
molecular size in determining transcellular transport has been underscored in various 
investigations. In the case of peptides, hydrogen bonding capacity deserves special mention. 16, 20 
As discussed in the preceding paragraph, ∆log PC and log P heptane/ glycol have been proposed as 
experimental surrogates of hydrogen bonding potential. Stenberg and coworkers proposed another 
parameter - dynamic polar surface area - as a predictor of hydrogen bonding capacity in peptidic 
solutes. 21 Polar surface area is defined as the area occupied by nitrogen and oxygen atoms 
(including their attached hydrogen atoms) in the peptide. Substracting the polar surface area from 
total surface area (calculated by the computer program MAREA 22) gives the nonpolar surface 
area. The dynamic nature of the various surface areas was deduced from the statistical average 
obtained by weighing the appropriate surface area of each low energy conformation by the 
probability of its existence according to a Boltzmann distribution. The dynamic polar surface area 
(PSA d) is proposed to describe the transfer of the peptide from the interface into the membrane 
interior, just like ∆log PC. The dynamic non-polar surface area (NPSA d) represents the transport 
of the peptide into the polar head group region (interface) of the lipid bilayer, a process described 
earlier by log PC octanol.  The authors found good correlation between PSA d and the permeability of 
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19 oligopeptides belonging to three homologous series. On the other hand, other reports indicate 
that the usefulness of PSA d is restricted to homologous series of peptides and fails when applied 
to structurally diverse peptides. 17, 18 
   
1.1.3 Active transport of oligopeptides 
 
 Most mammalian peptide transporter proteins belong to the Proton-coupled Oligopeptide 
Transporter (POT) superfamily, also known as the Peptide Transporter (PTR) family. The best 
known member is the Peptide Transporter 1 (PepT1), which is also the first peptide transporter to 
be identified in the brush border membrane of rabbit intestinal and renal epithelial cells. 23 This 
protein transports dipeptides, tripeptides (regardless of sequence) and numerous peptidomimetics. 
The expression of this protein in the intestine has made it the focus of many drug companies who 
attempt to incorporate structural features into their lead molecules that will enhance affinity for 
PepT1, and thus lead to greater oral bioavailability. A recent review proposes that the 
preoccupation with PepT1 may have led to improper conclusions being drawn on the transport 
kinetics of small peptides and peptidomimetics. 24 This is because there are several other putative 
peptide transporters (for example, the peptide histidine transporters) expressed in the intestinal 
epithelium and they are likely to contribute to the transport of oligopeptide as well. 
 
1.1.4 Transcytosis of oligopeptides 
 
 In transcytosis, the solute is first enclosed by a vesicle formed by the invagination of the 
apical membrane. The vesicle crosses the cytosol and fuses with the basolateral membrane, 
depositing the solute on the other side of the epithelial barrier. 25, 26 If the solute is released in the 
cytosol, the process is described as endocytosis.   
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 The solute may be internalised by binding specifically to receptor- like molecules on the 
membrane surface. Various immunoglobulins and growth factors are purportedly transported 
across membranes by such a receptor- mediated process. 27 Alternatively, transcytosis may occur 
by the non- specific adsorption of the solute to carrier molecules on the membrane surface. 
Positively charged solutes are more likely to be transferred in this manner because of their affinity 
for the negatively charged polysaccharides that are present in abundance on membrane surfaces. 29 
Another mode of translocation that has been described is that of non- specific fluid- phase 
transcytosis in which the solute (dissolved in extracellular fluid) is taken up in the internalised 
vesicle. The transport rate is dependent on both the concentration of the solute in the extracellular 
fluid and the rate of internalisation. 26 
 
 Shimizu and coworkers investigated the transepithelial transport of two metabolically 
resistant oligopeptides – the nonapeptide bradykinin and a tetrapeptide (Gly-Gly-Tyr-Arg) - across 
the Caco-2 monolayer. 5 The transfer of bradykinin across the Caco-2 cell monolayers was found 
to be unidirectional (apical- to- basolateral flux > basolateral- to- apical) and energy dependent 
(lower rates of flux observed in the presence of sodium azide and 2,4-dinitrophenol). The process 
was also unaffected by cytochalasin D which causes the opening of tight junctions by altering the 
cytoskeletal structure and bradykinin antagonists. Its apical- to- basolateral flux exceeds that of a 
marker for fluid phase transcytosis. Based on these observations, the authors posited that 
bradykinin is transported across the Caco-2 cell monolayers by adsorptive transcytosis. A similar 
pathway was also proposed for several bradykinin analogues, where, interestingly, the most 
hydrophobic member was transported at the fastest rate.  In the case of the smaller tetrapeptide, a 
paracellular route was proposed.   
 
 Adsorptive- mediated endocytosis across the Caco-2 cell monolayers was also proposed 
for a basic metabolically stable tetrapeptide (H-MeTyr-Arg-MeArg-D-Leu-NH2(CH2)8NH2). 27 
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The peptide was earlier reported to be efficiently taken up by brain capillary endothelial cells via 
the same process. 28   
 
1.1.5 Membrane translocation of oligopeptides 
 
  Another pathway for oligopeptides that has gained attention in recent years is the 
membrane translocation pathway, which is proposed to be a non- endocytotic and non- energy 
requiring route for peptides with a maximum of 30 amino acids. This pathway came to the fore 
when it was observed that living cells could internalise an 86 amino acid- long fragment from the 
HIV-1 Tat protein (Tat-86). 30 A similar observation was made for the Antennapedia protein of 
Drosophilia. 31 Further investigations revealed that the 60 amino acid homeodomain of the 
Antennapedia protein could be reduced to a 16 amino acid-long fragment with no loss of cell 
penetrating properties. 32 This fragment, subsequently called penetratin (pAntp), is the forerunner 
of several cell-penetrating proteins (CPPs). The significance of these peptides lies in their potential 
as delivery vehicles for bioactive molecules, namely, the ability to deliver their “cargo” without 
disturbing the stability of the cell membrane, demonstrable effective delivery in vivo in a variety 
of cell types and the absence of antigenic and immunogenic side effects.  33 
 
 The mechanism of the translocation process is still widely debated. The observation that 
uptake of CPPs is often unaffected by endocytosis inhibitors (like brefeldin A) argues against an 
endocytotic pathway. 34 In addition, the comparable rates of flux at 4 oC and 37 oC suggest an 
energy- independent mode of entry. 33 The involvement of a specific carrier or receptor is also 




 A common structural feature found among CPPs is the high content of basic amino acids, 
in particular arginine. 33 Using a series of linear and branched chain arginine-rich peptides, Futaki 
and coworkers showed effective internalisation of both linear and branched peptides, with an 
optimum number of approximately eight arginine residues. 36 The secondary structure of the 
peptide may be important as most CPPs are characterised by an α-helical structure. 33 
  
1.2 Angiotensin Peptides 
 
  The angiotensin peptides are generated in the renin- angiotensin- aldosterone system 
(RAS) via an enzymatic cascade. The precursor protein (angiotensinogen) is cleaved by renin to 
give the inactive decapeptide angiotensin I (Ang I) (Figure 2). The latter is hydrolysed by 
angiotensin converting enzyme (ACE) to give Ang II, which is further broken down by 
aminopeptidases to Ang III, Ang IV and di- and tri-peptides derived from their breakdown. 37 Ang 
II regulates blood pressure, fluid volume homeostasis and pituitary hormone release via types I 
and II angiotensin receptors (AT1 and AT2) located in the kidney, adrenal gland, and the 
cardiovascular and nervous systems.  Ang III has similar effects and it has been hypothesised that 
Ang III is the final mediator of some actions of Ang II. 38 Ang IV displays significantly lower 
affinities for the AT1 and AT2 receptors, unlike Ang II and Ang III which are full agonists at these 
receptors.   
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The receptor for Ang IV (AT4) has been identified to be a membrane protein called the 
insulin-regulated aminopeptidase (IRAP). 39 IRAP cleaves and inactivates a large number of 
physiological peptides such as oxytocin, vasopressin and Ang III. When Ang IV binds to AT4 
(IRAP), the catalytic activity of the enzyme is diminished. Thus, it is proposed that Ang IV 
prolongs the activity of labile peptides and this could form the basis of its pharmacodynamic 
action which includes among others, the ability to improve memory and learning. 40
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  Des- aspartate- angiotensin I (DAA-I) is a physiological peptide that is formed when the 
N-terminal amino acid (Asp) of Ang I is cleaved by an aminopeptidase. DAA-I is then hydrolysed 
by ACE to give Ang III. 41 Recent studies show that DAA-I has beneficial effects on the 
cardiovascular system, possibly through its anti-Ang II properties. For example, DAA-I attenuates 
Ang II– induced incorporation of phenylalanine in cultured rat cardiomycetes, 42 reduces the 
central pressor action of Ang II 43 and prevents the onset of cardiac hypertrophy in rats that have 
been undergone chronic coarctation of the abdominal aorta. 44 Sim and Qui reported that the 
plasma levels of DAA-I were significantly lower in hypertensive rats and hypertensive human 
patients. 45 When the latter subjects were treated with an ACE inhibitor (captopril), DAA-I levels 
showed a sharp rebound, prompting the authors to propose that this might be an important but 
hitherto unrecognised contributory factor to the effectiveness of ACE inhibitors. A recent report 
indicates that DAA-I is likely to be commercialised as an agent that could prevent the narrowing 
of blood vessels in patients. 46 The peptide will be delivered as drug- coated stents to be inserted 
into susceptible vessels of heart patients.  
 
  When DAA-I was administered orally or intravenously to rats that have been subjected to 
coarctation of their abdominal aortas, there was a significant delay in the onset of cardiac 
hypertrophy that is the normal consequence of such an action.  47 Its efficacy when given orally is 
encouraging although some of the orally administered DAA-I is undoubtedly degraded by 
intestinal peptidases to smaller peptides, including Ang III and Ang IV.  Ang III and Ang IV, as 
well as dipeptide and tripeptide fragments derived from their breakdown, have been found to 








2 AIM OF THESIS 
 
 The aim of this thesis is to obtain a better understanding of the transport properties of the 
angiotensin peptide DAA-I across the intestinal epithelium. DAA-I is a physiological peptide 
involved in the pathophysiology of the cardiovascular system. The therapeutic potential of DAA-I 
in the treatment of cardiovascular diseases (namely, the attenuation of post- infarction injuries and 
neointima growth in catheter injured arteries) is promising and would be enhanced further if it 
demonstrates good oral bioavailability. Preliminary investigations indicate that DAA-I is a stable 
peptide that can transverse the intestinal epithelium. 47 However, there are no details of the extent 
to which this process occurs or the route of transport involved. A systematic investigation of the 
transport properties of DAA-I across the Caco-2 cell monolayers, which is used as a cell culture 
model of the small intestinal epithelium, will address these issues in greater detail.  
 
Figure 3: Structures of DAA-1, Ang III and Ang IV 
 
DAA-I       2Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu10
          Ang III    2Arg-Val-Tyr-Ile-His-Pro-Phe8
               Ang IV           3Val-Tyr-Ile-His-Pro-Phe8
 
 
 The nonapeptide DAA-I is structurally related to Ang III and Ang IV (Figure 3). The loss 
of two C-terminal amino acids from DAA-I gives Ang III and the removal of the N-terminal 
amino acid (arginine) of Ang III results in Ang IV. Physiologically, these processes are mediated 
by ACE and aminopeptidases respectively. While preliminary reports point to DAA-I as a 
relatively stable peptide, some degree of enzymatic degradation is likely to occur in the intestinal 
lumen, leading to the formation of Ang III and Ang IV, among other degradation products.  An 
earlier investigation shows that Ang IV transverses the Caco-2 cell monolayers without 
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degradation. 49 Thus, it is of interest to compare the transport properties of these related peptides 
which differ in length but share a common core of amino acids. The hypothesis is that DAA-I, 
Ang III and Ang IV will display different physicochemical characteristics (lipophilicity, charge, 
hydrogen bonding potential) and shape (secondary structure) in accordance to their chain length 





TRANSPORT OF ANGIOTENSIN PEPTIDES ACROSS THE 
Caco-2 CELL MONOLAYERS 
 i
 





 When cultured on permeable inserts, Caco-2, a human colon carcinoma cell line, 
differentiates spontaneously to form confluent monolayers of polarised cells. Despite its colonic 
origin, Caco-2 cells acquire many features of intestinal cells during culture. For example, they 
become columnar in shape and form junctional complexes with well-developed brush-borders 
facing the medium. Several enzymes and transporters are also present in the differentiated Caco-2 
cells. 50 Since its introduction in the early 1990s, the Caco-2 cell culture model has become the 
unofficial standard used by the pharmaceutical industry as a convenient means of estimating the 
intestinal permeability of drug candidates. 
 
  The merits and limitations of the Caco-2 culture system as a surrogate model for 
intestinal absorption have been reviewed. 10, 51 The main advantages are its proven correlation with 
human absorption data, the ease and convenience associated with carrying out the transport 
experiments, and the mechanistic insight that can be derived from the results. 10 On the other hand, 
there are intrinsic limitations to its use, notably the absence of mucus production, the lack of 
cytochrome P450 enzymes, variable transporter expression, low levels of paracellular permeability 
and the inability to study regional intestinal differences in oral absorption. 51 The low level of 
paracellular permeability makes it difficult to obtain a reliable assessment of the permeability of 
solutes (among them, peptides and peptidomimetics) that are transported by this route.   
 
 Notwithstanding the usefulness of Caco-2 as an in vitro model, it has been acknowledged 
that the potential of this model will be further enhanced if there is a concerted effort to standardise 
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and control the growth conditions employed. 52, 53 Ingels and Augustijins have discussed 
discrepancies arising from the use of different media in transport experiments. 51 Cell culture 
conditions like time in culture, membrane support and seeding density have been noted to 
influence the morphology, formation of tight junctions, expression of peptide transporters and the 
efflux pump protein of the Caco-2 cells.  54 
 
 The purpose of this section is to evaluate the permeability of the angiotensin peptides 
(DAA-I, Ang III and Ang IV) on the Caco-2 cell monolayers and to characterise their transport 
properties under different conditions of temperature, concentration and in the presence of selected 
inhibitors. Prior to these investigations, it is necessary to establish methods to validate the integrity 
of the Caco-2 cell monolayers, quantify the amount of peptide transported, evaluate the stability of 
the peptides to enzymatic and non-enzymatic hydrolyses and assess the effect of the peptide and 




3.2.1 Materials  
 
Cell culture reagents Minimum Essential Medium (alpha medium), nonessential amino 
acids, Hank’s Balanced Salt Solution (HBSS), fetal bovine serum (FBS) were supplied by 
Gibco- BRL Life Technology (Grand Island, NY, U.S.A.). Penicillin G, streptomycin sulphate, 
N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES), trypsin- EDTA and 
colchicine were purchased from Sigma Aldrich Corporation (St. Louis, MO). Other chemicals 
were obtained from the following sources: Lucifer yellow CH, lithium salt (Molecular Probes, 
Eugene, Ore); 2,4-dinitrophenol (ICN Pharmaceuticals Inc, Plainview, NY); phosphate buffered 
saline (PBS) and ethylenediamine tetraacetic acid (EDTA) (NUMI Laboratory Supplies, 
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Singapore); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT (BDH, Poole, 
England). Angiotensins III and IV (95 % purity) were obtained from ICN Biomedicals Inc 
(Costa Mesa, CA) and used as received. Des-Asp1 - angiotensin I (DAA-I) was purchased from 
Bachem AG (Bubendorf, Switzerland) and purified to at least 97% purity before use. 
Radiolabelled peptides - [valine- U- 14C] des-Asp - angiotensin I (255 mCi/mmol), [tyrosine- 
(n)- 3H] Angiotensin IV (83 Ci/mmol) and [tyrosyl- 3,5 (n)- 3H] Angiotensin III (42 Ci/mmol) 
were custom synthesised  by  Amersham Biosciences (UK). All other chemicals and solvents 
were of analytical grade and they were used as received. 
 
3.2.2 Purification of crude des-Asp - angiotensin I 
 
Crude des-Asp - angiotensin I was purified by reversed- phase chromatography using a 
commercial C18 column (Inertsil ® ODS, particle size 10 µm, 10.0 mm x 250 mm) as stationary 
phase.  The mobile phase was 0.1 % trifluoroacetic acid (TFA) in distilled water (solvent A) and 
0.1 % TFA in 80 % acetonitrile (solvent B). Separation was carried out on a Waters 600 System 
HPLC. The peptide was eluted using a mobile phase gradient of 39- 44 % solvent B at a flow 
rate of 2 ml/min over a period of 40 minutes. The absorbance of the eluted peptide was 
monitored at wavelengths 215 nm and 280 nm, corresponding to the λmax of the peptide linkage 
and aromatic residues (Tyr 4, Phe 8) respectively.  
 
Fractions were collected at intervals of 45 seconds and screened again by HPLC. Those 
fractions that contained the pure peptide (identified by the presence of a band, which eluted over 
a period of 4- 5 minutes, on the chromatogram at a retention time characteristic of the peptide) 
were pooled (Appendix, Figure 1A). The presence of the pure peptide was confirmed by 
molecular mass determination by electrospray ionisation– mass spectroscopy (EMI-MS, LCQ 
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MS Detector, Finnigan) (Appendix, Figure 1B). It was then freeze-dried and stored in a 
desiccator (-20 oC). 
 
3.2.3 Caco-2 cell culture 
 
3.2.3.1 Culture of Caco-2 cells 
 
 Caco-2 cells were obtained at passage number 18 from the American Type Culture 
Collection (Rockville, MD, U.S.A.) and grown in 25 cm 3 tissue culture flasks (Cellstar ®) at 37 
oC in an atmosphere of 5 % CO2 using 5 ml MEM (pH 7.4) supplemented with 1 % (v/v) 
nonessential amino acids, 10 % (v/v) fetal bovine serum, 10 mg/L penicillin G, 10 mg/L 
streptomycin sulfate and 2 % (v/v) sodium bicarbonate solution [7.5 % (v/v)]. The medium was 
changed every other day until the cells reached 80- 90 % confluency.  Subculturing was then 
carried out at a split ratio of 1 to 3. To subculture the cells, the medium in the flask was removed 
using a pipette and the cells were gently rinsed twice with 5 ml PBS before they were 
“trypsinised” with a 1 ml solution of 0.5 % trypsin and 0.2 % EDTA. All but a small aliquot (0.3 
ml) of the solution was removed after one minute. The cells were left in contact with this small 
volume for about 5- 10 minutes at 37 oC under an atmosphere of 5 % CO2. 55 5 ml of MEM was 
then added to stop the trypsinisation and the cells transferred to a 75 cm 3 flask containing 10 ml 
medium. 
 
 Upon reaching 80- 90 % confluency in the 75 cm 3 flask, the Caco-2 cells (passage 
number 40- 50) were grown on Transwell ® cell culture chambers (12 wells, polycarbonate cell 
culture inserts, diameter 12 mm, pore diameter 0.4 µm) purchased from Costar Corporation 
(Cambridge, MA). Before the inserts were used, they were preincubated with culture medium 
(0.1 ml MEM on the apical side and 1.5 ml on the basolateral side) for 30 minutes. 0.5 ml of the 
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dispensed cells were then seeded on the apical surface of each insert at a density of 10 5 cells/ml 
and fed with fresh medium 1 day after seeding. The Caco-2 cells were grown on the apical end 
on the polycarbonate filter for a period of 21 to 30 days to obtain well- differentiated 
monolayers before they were used for experiments. Medium was changed every other day. 
 










3.2.3.2 Cryopreservation of Caco-2 cells 
 
For consistency, only cells with passage numbers of 40- 50 were used for the transport 
experiments. The cells were cryopreserved until they were required for experiments. 
Cryopreservation was carried out in the following way: cryovials were filled with aliquots of 
approximately 10 6 Caco-2 cells suspended in 1 ml of MEM medium containing 10 % DMSO as 
cryoprotectant. These vials were cooled gradually from room temperature to –80 oC by placing 
them overnight in a Nalgene Cryo 1 oC freezing container (Rochester, NY, U.S.A.) placed in a 
freezer (-80 oC). The vials were removed the next day and stored in a liquid nitrogen dewar until 
they were required for use.  
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3.2.3.3 Revival of Caco-2 cells 
 
Cryovials containing Caco-2 cells were carefully removed from the liquid nitrogen tank 
and thawed within two minutes in a 37 oC water bath. The cells were then transferred aseptically 
into a 25 cm 3 flask containing 4 ml of MEM and incubated at 37 oC in an atmosphere of 5 % 
CO2 for propagation.  
 
3.2.4 Monitoring integrity of Caco-2 cell monolayers 
 
The integrity of the monolayer was assessed by monitoring its transepithelial electrical 
resistance (TEER) and the transport of lucifer yellow across the monolayer.  Determination of 
TEER gives an indication of the confluence of the monolayer and the development of tight 
junctions. Lucifer yellow is transported across the monolayer via the paracellular pathway and 
the amount transported also reflects the integrity of the tight junctions. 5 Both methods were 
routinely applied to random wells in experiments involving cell monolayers. 
 
3.2.4.1 Transepithelial electrical resistance (TEER)  
 
Transepithelial electrical resistance (TEER) values were measured with a pair of 
microelectrodes (Millicell Electrical Resistance System) (Millipore, Bedford, MA, U.S.A.), 
starting from the second day after the seeding of the cells onto the Transwell ® and continued 
until the day for experiment. TEER values were obtained by subtracting the resistance of the 
bare filter insert from the total electrical resistance across the monolayer, after which the value 
obtained (= monolayer resistance) was substituted into Equation 1: 
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TEER   =     monolayer resistance x membrane area (1 cm2)    (1)             
         
Only monolayers with TEER values greater than 250 Ω cm2 in culture media were used 
for experiments. TEER values of randomly selected inserts were also monitored in the following 
manner:  The cells were fed with MEM 2 hours before the transport study, after which the TEER 
value of the monolayer was measured. 5 Subsequently, the monolayer was washed twice with 
Hank’s Balanced Salt solution containing 10 mM HEPES (HBSS- HEPES) (pH 7.4), 
equilibrated with HBSS- HEPES for 30 minutes at 37 oC and 5 % CO2, after which the 
resistance of the monolayer in HBSS- HEPES was measured. Finally, the TEER of the 
monolayer was determined at the end of the transport experiment.   
 
3.2.4.2 Transport of lucifer yellow  
 
 The flux of lucifer yellow across the monolayer was determined concurrently in 
randomly selected wells. After the initial washing and incubation with HBSS- HEPES, lucifer 
yellow (0.5 ml of 100 µM) was added to the apical chamber while 1.5 ml of HBSS- HEPES was 
added to the basolateral compartment. An aliquot (100 µl) was withdrawn to determine the 
initial fluorescence of lucifer yellow. Thereafter, aliquots (100 µl) were withdrawn from the 
basolateral compartment at 30-minute intervals over 2 hours. With each withdrawal, an 
equivalent volume of HBSS- HEPES buffer was added to replace the volume removed. The 
fluorescence intensity of lucifer yellow was determined at excitation and emission wavelengths 
of 430 nm and 535 nm respectively on a microtitre plate reader (Tecan Group Ltd, 
Maennedorf, Switzerland). The amount of lucifer yellow transported was determined from a 
calibration curve of fluorescence intensity versus concentration (Appendix, Figure 2).   
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3.2.5 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to 
assess viability of Caco-2 cells 
 
The MTT assay was used to assess the viability of the Caco-2 cells in the presence of 
the peptides (des-Asp - angiotensin I, angiotensin III and angiotensin IV) and chemicals used as 
inhibitors in the transport experiments (2,4-dinitrophenol, sodium azide, EDTA and colchicine).  
 
Caco-2 cells that had reached 80- 90 % confluency were trypsinised, diluted to a 
concentration of 4.4 x 10 5 cells/ml using the same culture medium and 100 µl aliquots were 
added to each well of a 96- well plate (Nalge Nunc International, Rochester, NY, U.S.A.). The 
cells were incubated for 51 hours at 37 oC, 5 % CO2 for the cells to be attached to the walls of 
the well and to reach 80- 90 % confluency. At the end of this period, the test compounds 
prepared in HBSS- HEPES were added to give the following final concentrations in the well: 1 
mM peptides; 0.5 mM 2,4-dinitrophenol; 25 mM sodium azide; 1.25, 2.5, 5 and 10 mM EDTA; 
0.1 µM and 1 µM colchicine. Eight replicates were made for each concentration. 0.2 mg/ml of 
dextran and 5 % SDS were used as negative and positive controls respectively. Wells without 
cells (only HBSS- HEPES) and wells with only cells in culture media were examined in parallel. 
The 96- well plate was incubated for another 2 hours, after which the samples were decanted 
and an aliquot of MTT (100 µl, 0.5 mg/ml in pH 7.4 HBSS- HEPES buffer) was added to each 
well and incubated for another 3 hours. After this time, the MTT solution was removed by 
careful pipetting and each well was rinsed gently with 150 µl PBS to remove excess MTT. Care 
was taken to prevent the cells from detaching from the well during this process. DMSO (150 µl) 
was then added to each well to dissolve the formazan crystals that were formed when the 
mitochondria of viable cells reduced the MTT. The absorbance of the formazan product was 
measured after 5 minutes at 590 nm using a microtitre plate reader. The absorbance values 
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obtained at each concentration were averaged, adjusted by subtraction of blank values and 
expressed as a percentage of the average absorbance obtained from control incubations (cells 
with HBSS- HEPES).  The viability of Caco-2 cells in the presence of the peptide or inhibitor is 
given by Equation 2: 
 
      [ optical density of sample – optical density of blank ] x 100 %      (2) 
      optical density of cells in HBSS- HEPES – optical density of blank 
 
3.2.6 Peptide stability 
 
3.2.6.1 Stability of the peptides in HBSS- HEPES buffer (pH 7.4) 
 
           The peptide was dissolved in HBSS- HEPES buffer (pH 7.4) to form a 1 mM solution. 
An aliquot (0.5 ml) was dispensed into a well and incubated for 2 hours at 37 oC and 5 % CO2. 
The amount of the peptide was determined at the beginning and at the end of the incubation 
period by HPLC, with N-Benzoyl-Gly-His-Leu (Sigma Aldrich Corporation, St. Louis, MO) as 
internal standard, using an X-Terra ® Phenyl column (5 µm, 3.9 mm x 150 mm) and 0.1 M 
ammonium acetate (pH 7.4) in 20- 21 % acetonitrile (flow rate of 1 ml/min) as mobile phase. 
The peptides were detected at wavelengths of 215 nm and 280 nm and identified by their 
retention times and by ESI- MS. 
 
3.2.6.2 Metabolic stability of the peptides 
 
The metabolic stabilities of the angiotensin peptides were examined by incubating the 
peptide (1 mM, HBSS- HEPES) with Caco-2 cell monolayers grown on 12- well plates ((Nalge 
Nunc International, Rochester, NY, U.S.A.) as described in the following paragraph. 56, 57
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The 12- well plates were seeded with Caco-2 cells and cultured for 21- 30 days. During 
the examination of metabolic stability, the Caco-2 cell monolayers were rinsed with the 
transport medium (HBSS- HEPES, pH 7.4) and then incubated with the same media for 30 
minutes at 37 oC, 5 % CO2. After incubation, media was removed from the wells and replaced 
with 1.5 ml peptide solution (1 mM). The 12- well plate was then incubated for 2 hours at 37 oC, 
5 % CO2, after which the solution in each well was collected, freeze-dried and stored at -80 oC 
until analysed. The amount of peptide was quantified by HPLC using the system described in 
Section 3.2.6.1 and its identity confirmed by mass spectroscopy.  
 
3.2.7 Transport of peptides across Caco-2 cells  
 
3.2.7.1 Transport of non- radiolabelled peptides 
 
           The transepithelial transport of the peptides (des-Asp - angiotensin I, angiotensin III and 
angiotensin IV) was examined by determining the bidirectional (AÆB: apical- to- basolateral; 
BÆA: basolateral- to- apical) rates of transport. Inserts with cell monolayers were rinsed with 
HBSS- HEPES pH 7.4. Aliquots of the same media were added to the apical (0.5 ml) and 
basolateral (1.5 ml) chambers. After an incubation period of 30 minutes at 37 oC and 5 % CO2, 
media was removed from both chambers and replaced with peptide solution (0.5 ml of 1 mM) in 
the apical chamber and 1.5 ml of HBSS-HEPES in the basolateral chamber. Addition of the 
peptide solution was designated time zero and at 20 minutes, 40 minutes and 80 minutes from 
this time, the contents of selected wells (apical and basolateral chambers) were removed, freeze-
dried and stored at –80 oC until they were analysed by HPLC using the system described in 
Section 3.2.6.1. The transport experiments were repeated at 4 oC.  
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The peptide is characterised by its apparent permeability coefficient P app calculated from 
Equation 3: 
 
                                               Papp  =  (dQ/dt) x (1/A) x (1/C0)                                                  (3) 
 
where (dQ/dt) is the steady state rate of appearance of peptide in the receiver chamber; C0 is the 
initial peptide concentration in the donor chamber; and A is the area of the Transwell ®.  
 
           The difference in the bidirectional transport rates was obtained from the permeability 
directional ratios (PDR), calculated from Equation 4:  
 
                                      PDR = (Papp  AP  to  BL)/ (Papp  BL  to  AP)                                                      (4)             
 
where (Papp AP to BL) is the permeability coefficient in the apical- to- basolateral direction and (Papp 
BL to AP) is the permeability coefficient in the basolateral- to- apical direction.  
           
 
3.2.7.2 Transport of radiolabelled peptides 
 
 The bidirectional transport of radiolabelled des-Asp - angiotensin I, angiotensin III and 
angiotensin IV at 37 oC and 5 % CO2 was also examined. To initiate the experiment, the cell 
monolayers were incubated with HBSS- HEPES buffer (pH 7.4) for 30 minutes at 37 oC, 5 % 
CO2 as described above. The entire contents of both chambers were then withdrawn and the 
apical chamber was replaced with 0.5 ml of radiolabelled peptide solutions with final 
concentrations in the well ranging from 1 nM to 10 µM while the basolateral chamber was 
replaced with 1.5 ml of HBSS-HEPES buffer. At time zero (= addition of peptide), aliquots (100 
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µl) were withdrawn from the peptide stock solution and the basolateral chamber. This was 
followed by sampling (100 µl) of the basolateral chamber at every 30 minutes for 2 hours. With 
each withdrawal, an equivalent volume of HBSS- HEPES buffer was added to replace the 
volume. At the end of 2 hours, an aliquot (100 µl) was withdrawn from the apical compartment 
for mass balance determination. 2 ml scintillation cocktail (Amersham Biosciences, UK) was 
added to the samples and radioactivity counted on a Packard Cobra Auto-Gamma 5002 series 
gamma counter with a counting efficiency of 72 %. The calibration curves relating concentration 
of peptide to radioactivity (counts per minute) are given in the Appendix, Figure 3.  
 
 A similar procedure was followed to determine the rates of basolateral- to- apical 
transport except that the peptide (1.5 ml) was added to the basolateral chamber and aliquots 
withdrawn from the apical chamber at 30-minute intervals for 2 hours. The bidirectional 
transport of radioactive peptides was also determined at 4 oC. 
 
3.2.7.3 Transport of peptides in the presence of inhibitors 
 
Inhibitor solutions (0.5 mM 2,4-dinitrophenol, 25 mM sodium azide, 1.25 mM EDTA or 
1 µM colchicine) were prepared in HBSS- HEPES (pH 7.4) buffer. The transport experiments 
were carried out at 37 oC and 5 % CO2 as before, but this time, the cell monolayers were 
incubated for 30 minutes with the inhibitor solution in the apical chamber (instead of transport 
media). At the end of 30 minutes, the inhibitor solution was removed and replaced with a 
solution (0.5 ml) consisting of the radiolabelled peptide (1 µM des-Asp - angiotensin I, 1 nM 
angiotensin III or 1 nM angiotensin IV) and the inhibitor (at the same final concentration used 
for incubation). At the start of the experiment (zero time), an aliquot (100 µl) was withdrawn 
from the stock solution (peptide and inhibitor) and the basolateral chamber to determine the 
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baseline radioactivity. Thereafter, 100 µl aliquots were withdrawn every 30 minutes over 2 
hours for scintillation counting. An equal volume of transport media containing inhibitor was 
added to the basolateral chamber to replace the amount removed.  
 
3.2.8 Statistical analysis 
 
Data are expressed as the mean ± standard error (SE). Linear regression, Independent-
samples T test and One-way ANOVA (SPSS 11.0, SPSS Inc., Chicago, IL) were used to compare 
the Papp data, with p set at 0.05 and smaller (p < 0.05) for statistically significant correlations.  
 
3.3 Results and Discussion 
 
3.3.1 Monitoring integrity of Caco-2 cell monolayers 
 
Two methods were employed to validate the integrity of the monolayers prior to their use 
in transport experiments. The 1st method involved the measurement of the transepithelial electrical 
resistance (TEER), which required determining the resistance of the monolayer to ion flux via the 
tight junctions. The 2nd method involved measuring the flux of a hydrophilic fluorescent marker 
(Lucifer yellow) that is transported across the monolayer via the water-filled pores of the tight 














Lucifer yellow (lithium salt)  
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One criticism of using TEER as a means of monitoring membrane integrity is that a 
change in electrical resistance may not necessarily reflect a change in solute flux across the 
paracellular route. 58 Despite these misgivings, TEER measurements are routinely carried out in 
many laboratories handling Caco-2 cells, more often as a means of ensuring uniformity (at least in 
terms of electrical resistance) of the cell line used in transport experiments. It was also employed 
in this capacity in the present investigation. 
 
Figure 5 shows the typical changes in the electrical resistance of the Caco-2 cell 
monolayers, starting from Day 1 when the cells were seeded onto the inserts, up to the time (Days 
21- 30) when the cells were used in transport experiments. TEER values were calculated using 
Equation 1 (Section 3.2.4.1) and expressed as mean (± standard error) of at least 5 cell 
monolayers.  
 
Figure 5. Change in transepithelial electrical resistance of Caco-2 cell monolayers grown on Transwell polycarbonate 

















































 Once seeded on the inserts, TEER values of the monolayer increased from 94 ± 14 Ω cm2 
(Day 1) to 549 ± 31 Ω cm2 (Day 3), with peak values (664- 760 Ω cm2) observed at Days 11-15. 
Thereafter, the values decreased and were maintained over the range of 250– 500 Ω cm2 from Day 
16 onwards. Transport studies were performed only on cells that were grown on the inserts for at 
least 21 days (i.e. from Day 21 onwards), and which had presumably attained an optimal level of 
transport proteins. 50 To ensure reproducibility of data, only monolayers with TEER values greater 
than 250 Ω cm2 in culture medium were used for transport experiments. 
 
 In the course of the transport experiments, the culture media was removed and the cells 
incubated in Hank’s Balanced Salt solution containing 10 mM HEPES (HBSS- HEPES, pH 7.4– 
“transport media”) up to a maximum of 2 hours. It was observed that a change from culture media 
to transport media caused a decrease in TEER. In one concurrent determination, the TEER values 
of cells maintained in culture media was 394 Ω cm2 (± 18, n= 5) while those incubated for 30 
minutes in transport media was 276 Ω cm2 (± 45, n= 5). This was equivalent to a decrease of 29 
%, indicating that a widening of the tight junctions occurred when the monolayer was exposed to 
the less physiological transport media. In view of these results, the transepithelial resistance of 
cells in transport media was monitored during the incubation period of 2 hours, in order to detect 
changes in the resistance of the monolayer during this period. Such information would allow a 
more accurate interpretation of the results of the transport experiments. To illustrate, when the 
apical- to- basolateral (APÆBL) transport of DAA-I (10 µM) was investigated, the TEER value of 
the monolayer in transport media was determined before addition of the peptide solution. On 
completion of the experiment 2 hours later, the peptide solution was removed, the monolayer was 
rinsed with fresh transport media and the transepithelial electrical resistance measured again. This 
procedure was repeated for transport experiments carried out using (i) varying concentrations of 
peptide, (ii) in the presence of various inhibitors/ chemicals (2,4-dinitrophenol, colchicine, sodium 
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azide, EDTA), and (iii) at different temperatures (37 oC, 4 oC). The actual TEER values for each 
transport condition are given in the Appendix (Tables 1A, B). Only monolayers with TEER values 
greater than 161 ± 7 Ω cm2 in HBSS- HEPES were to be accepted and the actual values found 
from the experiments (Appendix, Tables 1A, B) were found to satisfy this criterion. 
 
In view of the limitations associated with TEER measurements, the transport of lucifer 
yellow was determined concurrently to verify tight junction integrity during the period of the 
transport experiment. The amount of lucifer yellow transported was quantified from its 
fluorescence, and correlated to concentration from a pre- determined calibration curve (Appendix, 
Figure 2).  
 
The APÆBL and BLÆAP transport rates of lucifer yellow were not found to be 
significantly different, as would be expected for a substance that is transported by the paracellular 
route (Figure 6). Papp was estimated to be 55.6 (± 5.57) x 10-10 cm/sec. The addition of 1.25 mM 
EDTA increased the Papp [100.1 (± 33.4) x 10-10 cm/sec] while reducing the temperature to 4 oC 
had no significant effect on its permeability (Papp= 77.1(± 3.04) x 10-10 cm/sec). The transport of 
lucifer yellow across the monolayer was estimated to be less than 2.11 % (± 0.41) per hour (n = 
26). This low level of permeation falls within the range of paracellular markers. 10   
 
 Thus, the routine monitoring of transepithelial resistance and the flux of lucifer yellow 
served as a convenient means of standardising and validating (to an extent) the Caco-2 cells used 
for the transport experiments. 
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3.3.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to assess 
viability of Caco-2 cells 
 
 The peptides, transport inhibitors and other chemicals used in the present investigations 
may adversely affect the viability of the Caco-2 cells. This effect is likely to be concentration 
dependent. Thus it is necessary to ensure that the peptides and other chemicals were investigated 
at appropriate concentrations that did not interfere with cell viability. The MTT assay was 
employed for this purpose. 
 
 The MTT assay is a rapid and fairly precise method widely employed to assess cell 
viability. 59 It is based on the premise that living and/ or reproducing cells contain active 
mitochondria which produce mitochondrial succinate dehydrogenase. The tetrazolium salt, 3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is a substrate of this enzyme. As 
shown in Figure 7, MTT is reduced to purple formazan in viable cells. The formation of formazan 
is monitored spectroscopically (λmax = 590 nm) and the amount produced reflects the viability of 
the cells. When the cell viability is compromised by cytotoxic substances or unfavourable growth 
conditions, less formazan is produced.  
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epithelial tight junctions, and this would be expected to adversely affect cell growth and 
proliferation.   
 
 Thus the transport experiments could be carried out with concentrations of peptide up to 1 
mM without adverse effects on the Caco-2 cells. In the case of the inhibitors, the concentrations 
were capped at the following levels: 0.5 mM 2,4-dinitrophenol, 25 mM sodium azide, 1.25 mM 
EDTA and 1 µM colchicine.   
 
Table 2. Percentage viability (± standard error, n = 8) of Caco-2 cells exposed to various concentrations of peptides and 
inhibitors.   
 
Compounds Percentage Viability (± SE) (%) a
HBSS- HEPES 100  
Dextran (0.2 mg/ml) (Negative control) 94.3 ± 2.24 
SDS (5 %) (Positive control) 0.657 ± 0.733 
Des- Asp - angiotensin I (1 mM) 95.7 ± 2.56 
Angiotensin III (1 mM) 93.2 ± 1.37 
Angiotensin IV (1 mM) 97.4 ± 2.82 
2,4-Dinitrophenol (0.5 mM) 85.2 ± 1.54 
Sodium azide (25 mM) 88.9 ± 2.15 
EDTA (10 mM) 7.71 ± 2.36 
EDTA (5 mM) 11.9 ± 2.51 
EDTA (2.5 mM) 20.6 ± 1.11 
EDTA (1.25 mM) 96.9 ± 1.41 
Colchicine (1 µM) 80.6 ± 2.98 
Colchicine (0.1 µM) 102.5 ± 2.19 
a Cell viability was determined using Equation 2 ( Section 3.2.5) 
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3.3.3 Peptide stability 
 
 The stability of the angiotensin peptides was examined under two conditions: (i) in the 
presence of the transport buffer (HBSS- HEPES, pH 7.4) to establish if the peptides were 
susceptible to non- enzymatic hydrolysis at physiological pH, and (ii) in the presence of the Caco-
2 cells to determine if the peptides were susceptible to hydrolysis by enzymes produced by the 
cells.   
 
 Table 3 records the percentage of peptide recovered after a solution of the peptide (1 mM) 
in HBSS- HEPES (pH 7.4) was incubated for 2 hours at 37 oC, 5 % CO2.  All the peptides were 
stable in HBSS- HEPES buffer (pH 7.4) as seen from the high levels of peptide recovered after the 
incubation period. The identity of the peptide was confirmed from its retention time in the HPLC 
chromatogram (Appendix, Figure 4A), as well as the absence of extra peaks which would indicate 
the formation of breakdown products. These results show that the peptides were stable in the 
transport media under the experimental conditions (Table 3). 
 
Table 3. Percentage of DAA-I, Ang III and Ang IV recovered after an incubation period of 2 hours in HBSS- HEPES 
buffer (pH 7.4) at 37 oC. 
 
  Percentage of Peptides Recovered 
Des-Asp –  angiotensin I 104.1 ± 0.371 
Angiotensin III 93.5 ± 1.98 
Angiotensin IV 99.3 ± 0.0500 
 
 Caco-2 is known to express at least 8 aminopeptidases, such as aminopeptidases N and P, 
and dipeptidylaminopeptidase-IV, which are capable of hydrolysing the angiotensin peptides. The 
stability of the peptides was assessed from incubation experiments using Caco-2 cell monolayers 
grown on 12-well plates containing transport media over a period of 2 hours. In the presence of 
enzymatic breakdown, the concentration of the peptide in the well would decrease, and breakdown 
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products would be observed on HPLC analysis. The results showed that Ang III and Ang IV did 
not undergo significant enzymatic breakdown in the presence of the Caco-2 cells (Table 4). There 
was almost complete quantitative recovery of these peptides after the incubation period and no 
additional peak was observed in the HPLC chromatogram of the incubation solution after 2 hours 
(Appendix, Figures D, E). On the other hand, DAA-I was more susceptible to enzymatic 
hydrolysis (Appendix, Figures B, C). About 30 % of the peptide was hydrolysed on incubation, as 
estimated from mass balance determination. The main degradation product was Ang IV, as 
deduced from the retention time and mass determination of the extra peak eluted from the column 
(Appendix, Figures 4B, C). No Ang III (which is metabolically stable) was detected.  This may 
mean that the formation of Ang IV from DAA-I did not involve Ang III as an intermediate.   
 
 Therefore, Ang III and Ang IV were found to be stable to enzymatic and non- enzymatic 
hydrolyses. The results of their transport experiments could be expected to be readily interpreted 
as they would not be complicated by stability issues. On the other hand, DAA-I was stable to non-
enzymatic hydrolysis but was broken down by about 30 % in the presence of Caco-2 cells.  
 
Table 4.  Recovery of des-Asp - angiotensin I, angiotensins III and IV in the presence of Caco-2 cells after an 
incubation period of 2 hours in HBSS- HEPES (pH 7.4) 
 
 Percentage of Peptides Recovered after 2 hours Incubation in 
the Presence of Caco-2 Cells 
Des-Asp – angiotensin I 71.4 ± 1.60 
Angiotensin III 103.5 ± 9.46 
Angiotensin IV 94.4 ± 12.7 
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3.3.4 Transport of peptides across Caco-2 cells 
 
The bidirectional transport of DAA-I, Ang III and Ang IV across the Caco-2 cell 
monolayers was investigated under the following conditions: (i) varying concentrations, (ii) 
different temperatures (37 oC and 4 oC), and (iii) in the presence of transport inhibitors.   
 
The three peptides were investigated at concentrations ranging from 1 nM to 1 mM. If 
transport of these peptides was carrier- mediated, flux would increase with concentration but only 
to a point, after which the rate of transport would level out due to saturation of the carrier 
molecule. If transport occurred by passive diffusion, a linear increase in flux with concentration 
could be expected. Preliminary experiments showed that the permeability of the peptides was 
rather poor (Papp ≈ 10 -9 to 10 -8 cm/sec). A chromatographic system was developed which 
permitted the simultaneous detection of the 3 peptides based on the ultraviolet absorbing 
properties of the peptide bonds and aromatic rings. This method was however limited by the 
sensitivity of detection, the lower limit of which was10 µM, 1 µM, 0.5 µM for DAA-I, Ang III 
and Ang IV respectively. At the anticipated levels of permeation (Papp ≈ 10 -9 to 10 -8 cm/sec), the 
peptides were not detected by chromatography. To improve the detection, radiolabelled DAA-I, 
Ang III and Ang IV were custom synthesised. Ang III and Ang IV were tritiated at the tyrosine 
ring while DAA-I carried a 14C label at the valine residue. Tritiation permitted a lower level of 
quantification (up to 10 pM of peptide) as compared to the 14C label in DAA-I (up to 10 nM). The 
calibration curves for these peptides are given in Figure 3 (Appendix). 
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The bidirectional transport of the three peptides was investigated at 37 oC and 4 oC. The 
lowering of temperature would slow down active carrier- mediated transport but would not have a 
significant effect on solutes that diffuse across the monolayer.  
 
Sodium azide and 2,4-dinitrophenol are metabolic inhibitors and would adversely affect 
energy- requiring transport mechanisms. Sodium azide interferes with oxidative enzymes and 
inhibits phosphorylation. 2,4-Dinitrophenol uncouples oxidative phosphorylation. Colchicine is 
known to perturb microtubule structure and to inhibit the transport of solutes via intracellular 
vesicles. 5 EDTA chelates Ca2+ ions, leading to the opening of the epithelial tight junctions.  Thus 
paracellular transport of solutes via the tight junctions will be increased in the presence of EDTA. 
Because these substances are general cell “poisons”, they have to be used at appropriate 
concentrations that do not cause outright death of the cells. Shimizu and coworkers investigated 
the effect of some inhibitors on the transport of bradykinin in the Caco-2 cell model at the 
following concentrations: colchicine 1 µM, sodium azide 25 mM and 2,4- dinitrophenol 0.5 mM. 5 
The MTT assay showed that sodium azide, colchicine and 2,4- dinitrophenol did not adversely 
affect cell viability at these concentrations (Table 2).  Therefore these concentrations were 
appropriate and could be used in the present study. EDTA was used at 1.25 mM as proposed by 
Gan and co-workers. 61 This concentration neither affected cell viability as seen from the MTT 
assay nor caused a drastic drop in TEER (Appendix, Table 1B). EDTA had been used by others 13 
at much higher concentrations (10 mM) in transport experiments, but these higher concentrations 
were not found to be appropriate for the present assay.  
 
3.3.4.1 Transport of DAA-1 across Caco-2 cell monolayers 
 
 The apparent permeability coefficients (Papp) for the transport of DAA-I at different 
conditions of concentration, temperature and presence of inhibitors are shown in Tables 5, 6 and 
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Figures 8, 9. DAA-I appeared to permeate the Caco-2 cell monolayers poorly, as can be seen its 
Papp values which were in the range of 10 -9 cm/sec.   
 
 DAA-I was investigated at 3 concentrations: (i)  1 mM using the non-radiolabelled peptide 
(detection by HPLC), (ii) 10 µM and 1 µM using the 14C- labelled peptide (detection by 
scintillation counting). No significant difference was observed in the rates of APÆBL flux at the 3 
different concentrations. The absence of a concentration dependent effect suggested that a carrier- 
mediated process was not in operation. A comparison of the APÆBL and BLÆAP permeability 
coefficients also revealed no significant difference at 10 µM and 1 µM. This had two important 
implications. Firstly, it suggested that the transport of DAA-I was not mediated by a carrier 
protein, as transport would be directional under these circumstances (APÆ BL > BLÆAP). 
Secondly, DAA-I did not appear to be a substrate of P-glycoprotein (Pgp), the ATP- dependent 
pump responsible for expelling drugs from the cytoplasm, thereby preventing their accumulation 
and transport. A substrate of Pgp would show a significantly higher flux in the BLÆAP direction.  
 
 The transport of DAA-I was not affected by temperature, when investigated at 1 mM and 
1 µM concentrations. The Papp values for APÆBL and BLÆAP transport were also not 
significantly different at 4 oC. This observation further supported the absence of a carrier- 
mediated transport route for the passage of DAA-I across the Caco-2 cell monolayers.    
 
 The effect of inhibitors was investigated at 37 oC at only one concentration (1 µM) of 
DAA-I. The choice of the latter concentration was based on findings that DAA-I exerted its 
pharmacological effects at low micromolar concentrations. For example, DAA-I at 1 µM inhibited 
Ang II-induced incorporation of [3H] thymidine in aortic muscle cells (indication of cell 
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proliferation and hyperplasia).  62 DAA-I was also detected in the plasma of normotensive adults 
in the picomolar range. 45     
 
 As seen from Table 6, the APÆBL flux of DAA-I was not significantly altered by the 
presence of the metabolic inhibitors (sodium azide and 2,4-dinitrophenol). This would be expected 
if an ATP-dependent carrier- mediated transport mechanism was not in operation. In addition, 
since the APÆBL flux was not affected by EDTA, a paracellular route of transport could be 
discounted. A transcytosis-related pathway involving intracellular vesicular transport was also 
ruled out as colchicine, an inhibitor of this process, had no significant effect on the flux of DAA-I.   
 
 Thus, the present evidence suggested that DAA-I was transported across the monolayer by 
a non- energy requiring and non-carrier- mediated process. The large size of DAA-I (a 
nonapeptide) would discount its transport via the tight junctions and this was further supported by 
the observation that EDTA did not significantly alter the flux of DAA-I. Passive transcellular 
diffusion may be a viable option in the transport of DAA-I across the Caco-2 cell monolayers, not 
withstanding the absence of a concentration dependent flux which would be expected if 




Table 5. Transport of DAA-I at different concentrations and at two different temperatures. 
 Des-Asp - angiotensin I Papp (± SE) (1 x 10
-10) (cm/sec) 
 37 oC 4 oC 
 APÆBL BLÆAP PDR APÆBL BLÆAP PDR 
1    mM 40.0 ± 26.7 8.33 4.80 50.0 ± 16.7 12.5 ± 2.5 4.00 
10  µM 66.7 ± 16.7 66.7 ± 16.7 1.00    
1    µM 70.0 ± 4.84 63.0 ± 7.23 1.11 66.7 ± 6.80 83.3 ± 0.00 0.801 
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Each bar represents the mean (± standard error) of 3 to 10 repeats.  
        AP Æ BL 







Table 6. Transport of DAA-I in the presence of inhibitors at 37 oC. 
Apparent Permeability Values (± SE) (1 x 10-10) (cm/sec) (37 oC) 
Peptide(s) 1 µM 14C-Des- Asp angiotensin I 
Transport direction/ 
Inhibitor(s) 
APÆBL BLÆAP PDR 
Absence of inhibitor, 37 oC 70.0 ± 4.84 63.0 ± 7.23 1.11 
Temperature reduction, 4 oC   66.7 ± 6.80 83.3 ± 0.00 0.801 
0.5 mM 2,4-Dinitrophenol 66.8 ± 16.2 75.2 ± 18.72 0.888 
25 mM Sodium azide 61.1 ± 5.57 44.4 ± 5.57 1.38 
1.25 mM EDTA 61.1 ± 5.57 72.2 ± 11.1 0.846 
1 µM Colchicine 47.2 ± 5.13 44.4 ± 3.52 1.06 
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Each bar represents the mean (± standard error) of at least 3 repeats.  
        AP Æ BL 
        BL Æ AP 
 44
3.3.4.2 Transport of Ang III across the Caco-2 cell monolayers  
 
 The stability studies indicated that Ang III was metabolically stable and did not undergo 
enzymatic or non-enzymatic hydrolysis to any marked extent. Not withstanding this favourable 
property, the permeability of Ang III (Papp ≈ 10 -9 to 10 -8 cm/sec) across the Caco-2 cell 
monolayers was very similar to that of its less stable precursor DAA-I. The Papp for APÆBL 
transport of Ang III was determined over a 10 6 fold concentration range (1 nM to 1mM) (Table 7, 
Figure 10). Concentration dependent APÆBL flux was observed with Ang III.   
 
 A comparison of the APÆBL and BLÆAP permeability coefficients revealed no 
significant difference in the rates of permeation over the concentration range of 10 nM to 1 µM. 
However, when investigated at a lower concentration of 1 nM, the APÆBL rate was found to 
exceed the BLÆAP rate by almost 3 fold (n = 10 determinations). Moreover, this difference was 
abolished when the experiments were carried out at 4 oC and when the bidirectional transport was 
investigated in the presence of metabolic inhibitors (sodium azide and 2,4-dinitrophenol) (Table 8 
Figure 11). The APÆBL fluxes of Ang III at 4 oC and in the presence of metabolic inhibitors, 
except EDTA, were also significantly reduced when compared to that observed at 37 oC, in the 
absence of inhibitors. These observations suggested that Ang III (at 1 nM) was transported by an 
energy- requiring and carrier- mediated route. Similar observations were made when Ang III 
transport was investigated in the presence of colchicine (loss of bidirectional transport, reduction 
of APÆBL flux), indicating that a receptor mediated transcytotic route might also be involved. 
However, a paracellular route could be discounted since EDTA did not abolish the directional 
transport of Ang III (APÆBL > BLÆAP) and APÆ BL flux was not significantly altered in the 
presence of EDTA.   
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 Thus the transport of Ang III may occur via more than one route, depending on its 
concentration. The present investigation indicated that at low concentrations (1 nM and possibly 
lower), the transport occurred via an energy- requiring route which may involve carrier mediated 
transport or receptor- mediated transcytosis. Further investigations need to be done to have a better 
understanding of the mechanisms of transport. At higher concentrations (10 nM and more), the 
asymmetry in bidirectional transport rates was abolished, suggesting that transport was mediated 
by a diffusion process.  
Table 7. Transport of Ang III at different concentrations and at two different temperatures. 
 Angiotensin III Papp (± SE) (1 x 10
-10) (cm/sec) 
 37 oC 4 oC 
 APÆBL BLÆAP PDR APÆBL BLÆAP PDR 
1    mM 26.6 ± 6.67 6.68 ± 4.10 3.98 66.7 ± 0.00 13.3 ± 0.00 5.02 
1    µM 85.7 ± 7.97 66.7 ± 11.8 1.28    
0.1 µM 104.0 ± 17.1  83.3 ± 9.61 1.25    
10  nM 122.3 ± 12.7 108.2 ± 24.9 1.13    
1    nM 147.3 ± 10.1 a, b 51.7 ± 6.31 2.85 52.8 ± 2.78 61.1 ± 3.52 0.864 
  







































0.1 µM Ang III (37 oC)
10 nM Ang III (37 oC)
1 nM Ang III (37 oC) 
1 nM Ang III (4 oC)
1 µM Ang III (37 oC)
Each bar represents the mean (± standard error) of 3 to 10 repeats.  
a. Represents significant difference (p < 0.05) (Independent samples T-test) between APÆBL and BLÆAP transport 
rates. 
b. Represents significant difference (p< 0.05) (One-way ANOVA) between APÆBL rates of Ang III at the two different 
temperatures.  
        AP Æ BL 
        BL Æ AP 
 
 
Table 8. Transport of Ang III in the presence of inhibitors at 37 oC. 
Apparent Permeability Values (± SE) (1 x 10-10) (cm/sec) (37 oC) 
Peptide(s) 1 nM 3H-Angiotensin III 
Transport direction/ 
Inhibitor(s) 
APÆBL BLÆAP PDR 
Absence of inhibitor,37 oC 147.3 ± 10.6 a 51.7 ± 6.31 2.85 
Temperature reduction,4 oC   52.8 ± 2.78 b 61.1 ± 3.52 0.864 
0.5 mM 2,4- Dinitrophenol 91.7 ± 7.17 b 72.2 ± 3.50 1.27 
25 mM Sodium azide 94.4 ± 5.57 b 108.5 ± 8.50 0.870 
1.25 mM EDTA 111.3 ± 5.67 a 66.7 ± 0.00 1.67 
1 µM Colchicine 111.1 ± 10.4 b 80.0 ± 6.23 1.39 
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Each bar represents the mean (± standard error) of at least 3 repeats.  
a. Represents significant difference (p < 0.05) (Independent samples T-test) between APÆBL and BLÆAP transport 
rates. 
b. Represents significant difference (p < 0.05) (One-way ANOVA) between APÆBL flux in the presence and absence 
of inhibitors and when the experiment was conducted at 4 oC. 
        AP Æ BL 
        BL Æ AP 
 
3.3.4.3 Transport of Ang IV across Caco-2 cell monolayers 
 
 The hexapeptide Ang IV is the shortest of the three angiotensin peptides investigated in 
this study. Like Ang III, it was metabolically stable. Ang IV was also the main breakdown product 
arising from the enzymatic hydrolysis of DAA-I. The Papp for APÆBL flux of Ang IV fell in the 
same range as that of Ang III and DAA-I. There was no evidence of concentration dependence in 
the APÆBL flux of Ang IV (Table 9, Figure 12). A comparison of the APÆBL and BLÆAP flux 
of Ang IV showed a significant difference between the two rates at all the concentrations 
investigated, except 0.1 µM. The latter observation might be due to an experimental error. With 
the exception of this concentration, the APÆBL rate was significantly greater than the BLÆAP 
rate at the other concentrations investigated. Therefore, a carrier- mediated transport mode might 
be in operation. Further support came from the observation that the APÆBL flux of Ang IV (1 
mM and 1 nM) was significantly reduced at 4 oC, as were the differences in the bidirectional 
transport rates at this temperature. However, the presence of sodium azide, 2,4-dinitrophenol and 
colchicine did not slow down the APÆBL flux of Ang IV, which would be expected if an energy 
dependent transport mechanism was in operation. Interestingly, sodium azide and colchicine (not 
2,4-dinitrophenol) abolished the difference in APÆBL and BLÆAP fluxes,  which was in keeping 
with how such inhibitors would affect an energy dependent carrier mediated process.  
 
 Therefore, the transport of Ang IV had some but not all the characteristics expected of an 
energy- dependent carrier- mediated route. In support of such a route was the directional character 
of transport which was observed over a wide concentration range, the diminished ABÆBL flux at 
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4 oC, and the equalisation of the APÆBL and BLÆAP rates at 4 oC and in the presence of some 
inhibitors. Against it was observed that the APÆBL flux was not decreased significantly by 
sodium azide, 2,4-dinitrophenol and colchicine.    
 
Table 9. Transport of Ang IV at different concentrations and at two different temperatures. 
 Angiotensin IV Papp (± SE) (1 x 10-10) (cm/sec) 
 37 oC 4 oC 
 APÆBL BLÆAP PDR APÆBL BLÆAP PDR 
1    mM 83.3 ± 9.61 a, b 17.8 ± 8.67 4.68 1.50  5.00 0.300 
1    µM 100.2 ± 16.8 a 13.3 ± 1.93 7.53    
0.1 µM 75.0 ± 11.3 47.2 ± 9.05 1.59    
10  nM 122.3 ± 22.3 a 38.9 ± 5.57 3.14    
1    nM 118.9 ± 9.70 a, b 58.3 ± 5.46 2.04 51.7 ± 3.90 a 38.3 ± 2.55 1.35 
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Each bar represents the mean (± standard error) of 3 to 10 repeats.  
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a. Represents significant difference (p < 0.05) (Independent samples T-test) between APÆBL and BLÆAP transport 
rates. 
b. Represents significant difference (p< 0.05) (One-way ANOVA) between APÆBL rates of Ang IV at the two different 
temperatures.  
        AP Æ BL 
        BL Æ AP 
 
Table 10. Transport of Ang IV in the presence of inhibitors at 37 oC. 
Apparent Permeability Values (± SE) (1 x 10-10) (cm/sec) ( 37 oC) 
Peptide(s) 3H-Angiotensin IV 
Transport direction/ 
Inhibitor(s) 
APÆBL BLÆAP PDR 
Absence of inhibitor,37 oC 118.9 ± 9.70 a 58.3 ± 5.46 2.04 
Temperature reduction,4 oC   51.7 ± 3.90 a, b 38.3 ± 2.55 1.35 
0.5 mM 2,4-Dinitrophenol 97.3 ± 6.72 a 56.7 ± 8.50 1.72 
25 mM Sodium azide 116.7 ± 9.53 94.5 ± 11.2 1.23 
1.25 mM EDTA 117.0 ± 0.00 77.9 ± 20.1 1.50 
1 µM Colchicine 117.0 ± 0.00 122.3 ± 5.33 0.957 
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1 nM Ang IV +  
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a 
Each bar represents the mean (± standard error) of at least 3 repeats.  
a. Represents significant difference (p < 0.05) (Independent samples T-test) between APÆBL and BLÆAP transport 
rates. 
b. Represents significant difference (p < 0.05) (One-way ANOVA) between APÆBL flux in the presence and absence 
of inhibitors and when the experiment was conducted at 4 oC. 
        AP Æ BL 




The following conclusions can be drawn from the transport experiments: 
(i) The angiotensin peptides had low rates of permeability across the Caco-2 cell monolayers. The 
Papp values of DAA-I, Ang III and Ang IV fell in the range of 10 –9 cm/sec, which was similar to 
that of the paracellular marker lucifer yellow. Other peptides had better levels of permeability 
across the Caco-2 cell monolayers. For example the Papp of the pentapeptide met-enkephalin was 
approximately 10 -8 cm/sec while that of the tripeptide thryrotropin releasing hormone (TRH) fell 
in the range of 10 -7 to 10 -6 cm/sec. 13, 63, 64 Artusson noted that substances (including peptides) that 
were absorbed in the small intestine but not in the colon had very low permeability coefficients in 
the Caco-2 model. 65 The angiotensin peptides might belong to this category of compounds. 
 
(ii) The angiotensin peptides were not substrates of the efflux protein Pgp because the BLÆAP 
flux was not observed to be significantly greater than the APÆBL flux. Although not reported in 
this study, the Caco-2 cells in this laboratory were noted to exhibit greater levels of digoxin (a 
substrate of Pgp) transport in the presence of verapamil (a Pgp inhibitor). Many peptides have 
been reported to be substrates of Pgp 66, 68, 13 and the present observation that the angiotensin 
peptides were not Pgp substrates is a desirable feature from the standpoint of oral bioavailability.  
 
(iii) None of the peptides were transported by the paracellular route as their APÆBL fluxes were 
not increased in the presence of EDTA. The large size of the angiotensin peptides (6-9 amino 
residues) may preclude their passage across the tight junctions.   
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(iv) The three angiotensin peptides appeared to transverse the Caco-2 monolayer via different 
mechanisms. The peptides differ in their length but share a common core of six amino residues 
(Val-Tyr-Ile-His-Pro-Phe) which is present in the shortest peptide Ang IV. The physicochemical 
properties (shape, lipophilicity, charge) of these peptides are likely to change as the chain length is 
altered and these may play an important role in influencing the transport route. 
 
(v) Based on the present observations, the transport of DAA-I had several characteristics of a non- 
energy requiring, non- carrier mediated route. Transcellular passive diffusion was a likely 
pathway. However, the flux of DAA-I was not concentration dependent, as would be expected if 
passive diffusion was in operation. It should also be noted that DAA-I is broken down to Ang IV 
in the presence of Caco-2 cells. The breakdown was not extensive (≈ 30%) and any Ang IV 
formed would be stable as seen from the present investigation, and transported across the 
monolayer as well. Unlike DAA-I, the transport of Ang IV showed some characteristics of an 
energy- requiring, carrier- mediated process. Thus the results obtained with DAA-I might include 
an input from Ang IV as well, but the final picture that emerged (non- energy requiring, non- 
carrier mediated) did not reflect the characteristics observed with independent Ang IV transport 
(energy requiring, carrier mediated).  It may be that the amount of Ang IV formed as a result of 
breakdown is “small” and thus not reflected in the final transport profile.   
 
(vi) There is more ambiguity concerning the transport routes of Ang III and Ang IV.  The present 
results suggested that more than one mode might be in operation for these peptides.  The transport 
of Ang III appeared to be concentration dependent, with passive diffusion observed at high 
concentrations (> 10 nM) and an energy requiring process at lower concentrations. With regard to 
the latter, most of the known peptide transporters (e.g. PepT1) handle di- and tri-peptides and are 
unlikely to recognise Ang III (a heptapeptide) as a substrate. Transcytosis of Ang III via an 
energy- requiring receptor mediated pathway might be a possibility. In the case of Ang IV, an 
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energy- requiring pathway appeared to be in operation over a wide concentration range but this 






EFFECT OF PEPTIDE STRUCTURE ON TRANSPORT 
PROPERTIES OF ANGIOTENSIN PEPTIDES 
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 The structural features of a peptide will determine its physicochemical characteristics and 
these will in turn influence the rate and extent to which it transverses the intestinal barrier. For 
example, di- and tri-peptides, regardless of their amino acid composition, are substrates of PepT1 
and will be actively transported across the intestinal wall. Paracellular transport is generally 
restricted to oligopeptides with five and fewer amino acid residues and there is a preference for 
positively charged peptides. The transcellular diffusion of oligopeptides is strongly influenced by 
the physicochemical properties of the solute (pKa, log P, solubility, hydrogen- bonding). The 
general consensus is that the hydrogen bonding potential of a peptide is an important determinant 
of transport potential, but there is less agreement as to which descriptors are the most appropriate 
surrogate markers for hydrogen bonding potential. 16, 17, 18, 19, 20, 21 The importance of the secondary 
structure of the peptide was underlined by the findings of Knipp and coworkers 67 who found that 
hydrophobic peptides with significant β-turn structures in solution are more lipophilic and thus 
more likely to permeate Caco-2 cell monolayers.   
 
 The angiotensin peptides DAA-I, Ang III and Ang IV demonstrated different transport 
characteristics when investigated on the Caco-2 cell monolayers. These peptides differ in length 
but share a common core of six amino acid residues (Val-Tyr-Ile-His-Pro-Phe). It is hypothesised 
that the physicochemical properties and structural characteristics of these peptides are sufficiently 
different to influence their transport properties across the monolayer. Therefore, the objective of 
this section is to investigate the lipophilicity, hydrogen bonding potential, surface area, volume 
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and secondary structure of the angiotensin peptides and to establish if these properties influence 






Angiotensins III and IV (95 % purity) were obtained from ICN Biomedicals Inc (Costa 
Mesa, CA) and used as received. Des-Asp1 - angiotensin I (DAA-I) was purchased from Bachem 
AG (Bubendorf, Switzerland) and purified by chromatography to at least 97% purity before use. 
The purification procedure is described in Section 3.2.2. 2,2,2-Trifluoroethanol, deuterated 
water, sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS), 2,2,2-trifluoroethyl-1,1-d2 alcohol 
were purchased from Aldrich Chemical Company (Milwaukee, U.S.A). Other chemicals were of 
analytical grade. 
 
4.2.2 Circular Dichroism (CD) Spectroscopy 
 
CD spectral measurements were collected using a spectropolarimeter (JASCO J-175) 
connected to a computer for data acquisition and processing, and with the following settings, 
sensitivity of 20 millidegrees, 0.5 seconds response time, bandwidth of 1 nm, speed of 20 nm 
min -1. Each measurement represents the average of 3 repeated scans made in steps of 1 nm. 
Spectra were collected from 280 nm to 190 nm using a cylindrical quartz cell with pathlength of 
1 mm. The latter was cleaned before use by soaking in concentrated nitric acid for 3 hours, 
followed by rinsing in water and ethanol. The cell was thoroughly rinsed with ethanol in 
between runs. Solutions of the peptide (0.5 mg/ml) were prepared in two solvents, 2, 2, 2-
trifluoroethanol (TFE) and deionised water (pH adjusted to 3.0, 4.0, 6.0, 7.4, 9.0 and 12.0 with 
 55
HCl or NaOH). The spectrum of TFE or deionised water (at a specific pH) was made prior to 
each run, after which the solvent was removed and the cell filled with the appropriate peptide 
solution in either TFE or deionised water. Baseline correction was made to the spectrum of the 
peptide depending on the solvent used.  Ellipticity values were expressed as molar ellipticities. 
 
4.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
One and two-dimensional 1H NMR spectra of DAA-I, Ang III and Ang IV were 
obtained using the 500 MHz Bruker Avance Spectrometer equipped with a variable temperature 
probe. The spectra were collected in deionised water (pH 3.0). 3 mg of the peptide was 
dissolved in a solvent mixture of 540 µl deionised water (pH 3.0), 60 µl deuterated water (D2O) 
and 5 µl of an aqueous solution of sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS, used as 
chemical shift standard). One-dimensional 1H NMR spectroscopy was done at the following 
temperatures: 10 oC, 20 oC, 25 oC, 30 oC, 35 oC. Total Correlated Spectroscopy (TOCSY) 
experiments were carried out by the presaturation of residual water during the relaxation delay, 
and a mixing time of 70 milliseconds.  Data was collected using the time-proportional phase 
increment (TPPI) method with a sweep width of 5000 Hz. Rotating frame nuclear Overhauser 
spectroscopy (ROESY) with a spin-lock of 300 milliseconds was also carried out. Spectra were 
processed using the XWINNMR software (Brüker, Inc). 
 
4.2.4 Molecular Modelling  
 
Molecular modelling was performed on a Silicon Graphics computer using the Insight II 
2000 (Accelrys Inc., San Diego, CA). The peptides were built according to their solution 
conformations deduced from CD and NMR data. Based on these results, DAA-I was built as a 
linear chain molecule; while Ang III and Ang IV were built with a beta (β) II turn at Tyr 3 and 
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Ile 4 and Ile 3 and His 4 respectively. As the peptide could have several conformations in 
solution, it was necessary to identify the most feasible low energy conformation.  This was done 
by subjecting the structure to molecular dynamics simulations using the annealing process as 
described in the following paragraph. 
 
After an initial minimisation and dynamics at 300 K, annealing was performed by 
heating the molecule to 900 K and then cooling to 300 K at steps of 100 K (that is, from 900 K 
to 800 K, 800 K to 700 K, etc). Consistent valence force field was applied for modelling 
dynamics and minimisation. Except for molecular dynamics at 300 K and 900 K, which were 
carried out for 20000 femtoseconds, molecular dynamics at other temperatures were carried out 
for 5000 femtoseconds. Tethering was performed at all temperatures except 300 K. A structure 
was saved for every 100th step in the simulation process. Using the Trajectory of Analysis 
module in the software, a plot of time (x-axis) versus energy (y-axis) was obtained and used to 
select the low energy conformation near the end of the plot. This was done for all temperatures, 
after which the “final” structure obtained for each temperature was subjected to further 
dynamics.  
 
The lowest energy conformations obtained at the different temperatures were then 
cooled to 300 K and “soaked” in water molecules of 5.00 Å thickness. This assembly of 
molecule and water was then subjected to molecular dynamics. An average conformation of the 
assembly was obtained from the energy versus time plot and subjected to minimisation – 100 
steps of steepest descent, followed by 4000 iterations of the conjugate gradient method. The 
minimisation run was terminated when the gradient was less than 0.6 kcal/moleÅ The final 
structure was extracted from the water molecules and taken to represent the low energy 
conformation of the peptide.  The surface area, polar surface area and volume of this 
conformation were determined using Insight II. It was also examined to detect the groups 
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involved in intramolecular hydrogen bonding. CLogP of the peptide was determined using the 
SYBYL 6.6 Molcad module based on the final conformation. 
 
4.2.5 Determination of lipophilicity by reversed phase HPLC 
 
 The lipophilicities of DAA-I, Ang III and Ang IV were determined from their capacity 
factors (k’) by a reversed phase HPLC method. This method involved determining the retention 
times of the peptides in at least 4 mobile phase compositions. The following conditions were 
used: Water Spherisorb ® S10 ODS1 (10 µm, 4.6 mm x 150 mm) as stationary phase, mixtures 
of methanol and phosphate buffered saline (pH 7.4) as mobile phase, flow rate of 1 ml/min and 
peak detection at wavelength of 215 nm. The phosphate-buffered saline was prepared by 
dissolving 2.38 g disodium hydrogen orthophosphate, 0.19 g potassium dihydrogen 
orthophosphate and 8.0 g sodium chloride in 1000 ml water and then adjusting pH to 7.4 using 
sodium hydroxide and phosphoric acid. 10 % acetone was added as a void volume marker to the 
peptide solution (10 -4 M) prepared in HBSS- HEPES (pH 7.4). The peptides were eluted using 
the following mobile phases: DAA-I (55, 60, 65, 70, 75 % methanol); Ang III (45, 50, 55, 60, 65 
% methanol) and Ang IV (40, 45, 50, 55, 60 % methanol).  Capacity factors (log k’) were 
calculated from Equation (5):  
                                                 log k’ = log [(RT – R0) / R0]                                                  (5)           
where log k’ is the capacity factor; RT is the retention time of peptide; R0 is the retention time of 
acetone.  
 
Log k’ was plotted against percentage of methanol in the eluting mixture. A straight line 
is obtained and extrapolation of the line to 0 % methanol (100% phosphate buffered saline) 
gives log Kw (logarithm of capacity factor determined in phosphate buffered saline, pH 7.4) of 
the peptide. 69
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4.2.6 Calculation of Hydrogen Bonding Potential 
 
The total number of potential hydrogen bonds that can be formed by the peptide was 
calculated by a method described by Stein. 70 This method involves identifying functional groups 
in the peptide that can function as hydrogen bond donors and acceptors, assigning “N” values to 
these groups (a list is given by Stein 70) and adding them up to give the hydrogen bonding 
potential of the peptide. However, not all of the hydrogen bonding groups will be available for 
intermolecular hydrogen formation (with water or the hydrated polar head groups in the lipid 
bilayer) as some of them may be involved in intramolecular hydrogen bonding. The extent of 
intramolecular hydrogen bonding was assessed from the minimised conformation of the peptide, 
constructed from CD/ NMR data and subjected to molecular dynamic simulations (Section 
4.2.4). The number of sites involved in intramolecular hydrogen bonding were subtracted from 
the total number of potential hydrogen bonds available in the peptide to give the number of sites 
available for intermolecular hydrogen bonding. 
 
4.3 Results and Discussion  
 
4.3.1 Determination of Solution Conformation 
 
 The primary structure of a protein is determined by the sequence of amino acids linked 
together by peptide bonds. This is the 1st level of protein structure. The higher levels (secondary, 
tertiary, quaternary) refer to the three-dimensional orientation of the protein in space.  In the case 
of short chain peptides like the angiotensin peptides investigated in this study, it is only necessary 
to consider their secondary structures. The secondary structure is the local arrangement of the 
polypeptide backbone. It may assume well- defined conformations, like for example, an α-helix, 
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β-sheet or β-turn. It may also exist in non-systematic conformations (disordered structures) or as a 
mixture of rapidly interconverting conformations.  
 
 The solution conformation of angiotensin II has been investigated by proton NMR and 
circular dichroism. 71, 72, 73 Both techniques supported the presence of an extended conformation of 
the backbone, with no identifiable secondary structure. This may be attributed to the flexibility of 
Ang II which is an octapeptide. Since DAA-I is one amino acid longer than Ang II, it can be 
expected to assume an extended conformation. Ang III and Ang IV are shorter peptides and it 
would be of interest to see if the reduction in length gives rise to secondary structure. The solution 
conformations of DAA-I, Ang III and Ang IV were investigated by both circular dichroism (CD) 
and 1H-NMR. 
 
4.3.1.1 Determination of solution conformation by Circular Dichroism (CD) Spectroscopy 
 
 Circular dichroism is observed when an optically active substance absorbs left and right 
handed circularly polarised light to different extents. It is a rapid and convenient method for 
characterising the secondary and tertiary structures of proteins. CD spectroscopy provides 
information on the solution conformation of peptides at equilibrium. When combined with more 
direct structural methods like X-ray diffraction or two-dimensional NMR, a meaningful 
interpretation of secondary structure can be obtained.    
 
 Information on the secondary structure of a peptide is generally obtained from the far-UV 
spectral region (190- 250 nm). This region records the absorbance of the peptide bond. The CD 
spectra show a positive band in the region of 190 nm (πÆπ*) and a negative band at around 215 
nm (nÆπ*) due to the presence of the amide linkage. The appearance and position of these bands 
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will depend on the secondary structure of the peptide. For example, the presence of an α-helix will 
give rise to a maxima (positive band) at approximately 190 nm and a minima (negative band) at 
approximately 210 nm. When a secondary structure is absent, the CD spectra will be characterised 
by numerous maxima and minima, frequently a minima at approximately 190 nm.   
 
 Peptides with aromatic side chains (phenylalanine, tyrosine, tryptophan) will absorb in the 
near-UV region (250-350 nm). These signals are generally weaker than those in the far-UV region. 
When hydrophobic or Van der Waals interactions occur between the aromatic rings, these are 
observed as positive bands in the region of 210- 220 nm.   
 
 The CD spectra of DAA-I, Ang III and Ang IV were collected in aqueous solutions of 
varying pH (3 -12) and in trifluoroethanol (TFE) at one concentration (0.5 mg/ml) (Figure 14).  
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Data was obtained by dissolving 0.5 mg/ml peptide in two solvents, TFE and deionised water (pH adjusted to 3.0, 4.0, 
6.0, 7.4, 9.0 and 12.0).  
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 The CD spectra of DAA-I in water (pH 3-12) and TFE shared many similar characteristics 
(Figures 14A, B). Negative ellipticities were observed at wavelengths below 200 nm while bands 
with small positive ellipticities were noted above 220 nm. The negative bands at 200 nm and 
below suggested that DAA-I existed as a mixture of random conformations. The positive bands at 
approximately 225- 230 nm were due to aromatic interactions, most likely involving Tyr 4, His 6, 
Phe 8 and His 9. The solvent properties of TFE are reputed to be favourable for inducing secondary 
structures in peptides. The close resemblance between the spectra obtained in water and TFE was 
a good indication that a random conformation predominated in DAA-I. The isoelectric point of 
DAA-I was estimated to be 8.76, which meant that the peptide is positively charged at pH values 
less than this value and negatively charged at pH values above it. However the CD spectra 
collected at pH 3 and 12 shared similar features (Figures 14A, B). The charge of the peptide may 
not play an important role in determining the secondary structure.  
 
 Positive ellipticities over the range 210- 220 nm were observed in the CD spectra of Ang 
III in water and TFE, which could be attributed to interactions among the aromatic residues (Tyr 4, 
His 5, Phe 8, His 9) (Figures 14C, D).  The spectra also indicated the presence of a β- turn in Ang 
III, depending on the solvent and pH conditions. This was deduced from the pattern of positive 
bands at approximately 195 nm followed by negative bands greater than 200 nm, a characteristic 
profile of a type I β- turn. For example, Ang III at pH 9.0 showed a positive band at 195 nm and a 
negative band at 203 nm (Figure 14D). A similar pattern was noted for spectra collected at pH 6, 
7.4 and 12. However, a different pattern was evident in the CD spectrum at pH 3 which showed a 
(small) negative band at less than 200 nm and a (small) positive band at approximately 205 nm 
(Figure 14C). A similar pattern, but of different magnitude, was seen in the spectrum collected in 
TFE. This was characteristic for a type II β- turn. At pH 4, the positive band appeared at less than 
200 nm and there was no evidence of negative bands. This suggested that a secondary structure 
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was absent at this pH. Thus, based on the analysis of the CD spectra, several conformations (type I 
β- turn, type II β- turn, random conformation) had been detected for Ang III depending on pH and 
solvent.  
 
 An analysis of the CD spectra of Ang IV showed the presence of aromatic ring 
interactions (positive bands in the region of 210- 220 nm) as in the case of DAA-I and Ang III 
(Figures 14E, F). A type II β- turn was evident in TFE and aqueous solutions of pH 3- 7.4 
(positive bands at approximately 195- 210 nm). The spectra collected at pH 9 and 12 were 
different – Ang IV might have a type I β- turn at pH 9 (positive peak at 195 nm, negative peak at 
205 nm) and a random structure at pH 12 (no clear maxima at approximately 200 – 210 nm).   
 
Table 11. Conformational characteristics of DAA-I, Ang III and Ang IV as deduced from CD spectroscopy.  
 
Peptides/ Solvent Open Type I βTurn Type II βTurn Aromatic-Aromatic 
Interactions 
DAA-I (TFE) 9   9 
DAA-I (pH3.0) 9   9 
DAA-I (pH 4.0) 9   9 
DAA-I (pH 6.0) 9   9 
DAA-I (pH 7.4) 9   9 
DAA-I (pH 9.0) 9   9 
DAA-I (pH 12.0) 9   9 
     
Ang III (TFE)   9 9 
Ang III (pH3.0)   9 9 
Ang III (pH 4.0) 9   9 
Ang III (pH 6.0) 9 9 9 9 
Ang III (pH 7.4) 9 9 9 9 
Ang III (pH 9.0) 9 9  9 
Ang III (pH 12.0)  9  9 
     
Ang IV (TFE)   9 9 
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Ang IV (pH3.0)   9 9 
Ang IV (pH 4.0)   9 9 
Ang IV (pH 6.0) 9  9 9 
Ang IV (pH 7.4) 9  9 9 
Ang IV (pH 9.0)  9  9 
Ang IV (pH 12.0) 9   9 
 
 The conformational characteristics of DAA-I, Ang III and Ang IV, as deduced from CD 
spectroscopy, are summarised in Table 11. The most important observation related to the 
difference in the conformation of DAA-I and the other peptides (Ang III and Ang IV). DAA-I did 
not appear to possess a defined secondary structure. This finding is not unexpected as Ang II (a 
shorter peptide) has been reported to lack secondary structure. 71, 72, 73 However, this does exclude 
the possibility of DAA-I assuming a secondary structure at some point of its interaction in the 
biological environment. There are reports of linear peptides with random solution conformations 
forming β turns when they approached a membrane surface. 74, 75 
 
 In the case of Ang III and Ang IV, secondary structures (β turns) were present together 
with random conformations in TFE and in aqueous solutions of certain pH values. Ang III 
appeared to have a greater variety of solution conformations (open, types I and II β turns, 
depending on solvent conditions) compared to Ang IV (Table 11).   
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A β- turn is a region of the peptide involving 4 consecutive residues where the peptide 
chain folds back on itself by nearly 180 o. There are two main types of β turns – type I β turn and 
type II β turn which differ in the orientation of the central peptide unit, specifically the φ (N–Cα) 
and ψ (Cα–C=O) angles of the second and third amino acid residues involved in the turn (Figure 
15).  For type I β turn, the φ and ψ angles for the second and third amino acid residues are -60 o, -
30 o and -90 o, 0 o respectively. For type II β turn, the φ and ψ angles for the second and third 
amino acid residues are -60 o, 120 o and 90 o, 0 o respectively. For both turns, intramolecular 
hydrogen bonding occurs between the carbonyl oxygen of residue i and the amide nitrogen of 
residue i + 3. Facile interconversion from type I to type II is possible by a flip of the central 






4.3.1.2 Determination of solution conformation by Nuclear Magnetic Resonance (NMR) 
Spectroscopy 
 
 The solution conformations of the angiotensin peptides were investigated using one- (1D) 
and two- (2D) dimensional 1H NMR in aqueous solutions of pH 3.0. 2D 1 H NMR spectra, 
TOCSY and ROESY, were carried out to identify the protons associated with the amino acids 
present in each peptide as well as to determine through-space ROE connectivity between the 
amino acids respectively. This identification is necessary for subsequent peak assignment in 1D 1H 
NMR analysis (Figure 16). 1D 1H NMR performed at 5 different temperatures permits amide 
temperature coefficients of the peptide to be determined, which in turn gives an indication of 
which protons are solvent-exposed and which are solvent-shielded. Only solvent-shielded protons 
can participate in intramolecular hydrogen bonding.  
 
 The amide proton for each amino acid was first identified and the change in its chemical 
shift was determined at various temperatures (10 oC, 15 oC, 25 oC, 30 oC, 35 oC). A plot of 
chemical shift (y-axis) against temperature (x-axis) gives a straight line, whose gradient (∆δ / K) 
was determined. If the amide proton of a particular amino acid is solvent-shielded, its chemical 
shift will not change significantly with temperature. Most investigators use a gradient (amide 
temperature coefficient) cut-off value of 4 ppb/ K to distinguish between protons which are 
solvent-shielded and solvent-exposed. If the gradient is less than 4 ppb/ K, the amide proton in the 
amino acid is considered to be solvent-shielded and likely to participate in intramolecular 
hydrogen bonding. If the gradient is greater than 4 ppb/ K, the amide proton is probably hydrogen 
bonded to the surrounding solvent molecules and unlikely to participate in intramolecular 
hydrogen bonding. However, amide temperature coefficients may not be very informative in the 
case of short peptides like the angiotensin peptides where intramolecular hydrogen bonds (even if 
present) may not be strong enough to withstand the increase in temperature. Table 8 gives the 
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amide temperature coefficients for each amino acid present in DAA-I, Ang III and Ang IV. The 
temperature coefficients for the amino acids in DAA-I, Ang III and Ang IV were more than 4 ppb/ 
K, indicating that intramolecular hydrogen bonding was not present in the three peptides, or if they 
were present, were relatively weak.   
 




























































Table 12. Chemical shift data for DAA-I (A), Ang III (B) and Ang IV (C).  
 (A)  
Residues in DAA-I Chemical Shift (ppb/ K) 
Val 3 7.6 
Tyr 4 8.2 
Ile 5 6.5 
His 6 8.4 
Phe 8 7.5 
His 9 4.9 
Leu 10 8.9 
   
(B) 
Residues in Ang III Chemical Shift (ppb/ K) 
Val 3 6.2 
Tyr 4 8.1 
Ile 5 6.6 
His 6 8.5 
Phe 8 8.1 
 
(C) 
Residues in Ang IV Chemical Shift (ppb/ K) 
Tyr 4 9.6 
Ile 5 11.9 
His 6 11.7 
Phe 8 8.9 
 
 The 2D- 1H NMR techniques TOCSY and ROESY were employed to provide information 
on the amino acids involved in maintaining secondary structure in the peptides. TOCSY provides 
information on the long-range connectivity of protons in each amino acid in the peptide, but not 
the connectivity between amino acids within the peptide. The latter information was obtained from 
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ROESY which shows NH-CαH connectivities (between the NH of the ith amino acid and CαH of 
the (i-1)th amino acid) as well as NH-NH connectivities between amino acids in the same peptide 
or between two linear peptides. It thus provides information on the distances between protons that 
are within the range of 1.9- 4.5 Å.  
 
 The ROESY spectrum of DAA-I revealed the presence of various cross-peaks (Figures 17 
AI-III). Through- space medium range connectivity (i, i+3) was observed between Ile 5 and Phe 8, 
which suggested the presence of a turn in DAA-I, thus bringing these two amino acid residues 
close to each other. However, the through-space ROE connectivity between these 2 residues was 
weak. In addition, an NH-NH cross peak was observed between Ile 5 and His 6.    
 
 In the case of Ang III, NH-NH cross-peaks were observed between Tyr 4, Ile 5 and Ile 5, 
His 6, which signifies the presence of a turn involving Val 3, Tyr 4, Ile 5 and His 6 (Figures 17 BI-
III). Similarly, the ROESY spectrum of Ang IV showed NH-CαH cross-peaks between Tyr 4, Ile 5 
and Ile 5, His 6 as well as His 6, Phe 8. This, together with the data obtained from NH-NH region 
which showed cross-peaks between Tyr 4, Ile 5 and Ile 5, His 6, indicated the formation of a turn at 
Tyr 4, Ile 5, His 6 and Pro 7 in Ang IV (Figure 17 CI-III). 
 
 The conformations of the peptides deduced from CD and NMR data were not always in 
agreement. The nature of CD is such that it provides information on the predominant 
conformation. NMR is more sensitive and is better placed to detect possible folded conformations 
of the peptide. The CD spectra were collected using lower concentrations of the peptide (0.5 
mg/ml) in contrast to the NMR spectra which used a concentration that was six-fold higher (3 mg 
/ml), a factor that would further contribute to its greater sensitivity.  
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 CD data indicated that DAA-I had a random conformation with no clearly defined 
secondary structure. No evidence of intramolecular hydrogen bonding was seen from the amide 
temperature coefficients. On the other hand, 2D NMR data suggested the presence of a secondary 
structure, possibly a turn involving lle 5, His 6, Pro 7,and Phe 8. This might be a minor 
conformation of DAA-I.  
 
 In the case of Ang III and Ang IV, CD data suggested the presence of secondary structures 
(β turns) and this was corroborated by NMR data. Turns involving the 2nd- 4th amino acids were 
indicated in both Ang III and Ang IV based on ROE connectivities. There was however no 
evidence of intramolecular hydrogen bonding from the amide temperature coefficients. Logically, 
intramolecular hydrogen bonds would be needed to stabilise these turns and their absence in this 
instance may be due to the short lengths of these two peptides and/ or the low population of the 












































































































































































































































































The TOCSY and ROESY spectra were measured in 90 % H2O/ 10 % D2O at pH 3.0 and 25 oC.  
m. denotes minor conformation. 
(         ) denotes through- space ROE connectivity. 
 
4.3.1.3 Molecular Modelling of the Angiotensin Peptides 
 
 Molecular modelling using the software Accelrys Insight II ®, 67, 76 was used to further 
investigate the secondary structure of the angiotensin peptides. The three- dimensional (3D) 
structures of the peptides were built using information provided from CD and NMR. After 
minimisation, the structures were validated by a Ramachandran plot analysis to confirm that the 
torsion angles used to construct the backbones of the peptides were appropriate.  
 
 As mentioned earlier, data from CD supports a random structure for DAA-I while the 
ROESY spectra point to the presence of weak interactions between Ile 5 CγH and Phe 8 NH. Since 
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CD reflects the predominant conformation, it was decided that DAA-I would be constructed as a 
linear peptide. Upon minimisation and molecular dynamics, two energetically favourable energy 
conformations were identified for DAA-1 (Figure 18A). The first conformation (A-I) had a bend 
at Tyr 4 and Ile 5 while the second conformation (A-II) was a straight chain. Ile 5 CγH and Phe 8 
amide proton were brought close to each other at the bend, which would explain the observed 
ROE connectivity between these residues. The close proximity of the aromatic rings His 6 and 
Phe 8 were observed in both conformations. In the bend conformation (Figures 18A-I), the 
aromatic rings of Tyr 4 and Phe 8 were also close to one another. These would explain the 
observations from CD which showed the presence of interactions between the aromatic rings.  
 
 Ang III was constructed with a type II β turn since this was observed in CD (pH 3) and 
further supported by ROE connectivities between Tyr 4, Ile 5 and Ile 5, His 6, which suggested a 
turn involving Val 3, Tyr 4, Ile 5 and His 6. The structure was minimised and subjected to 
molecular dynamics. Two energy favourable average conformations were identified (Figure 18B), 
both of which supported the presence of a turn at the above-mentioned amino acids.  The φ and ψ 
angles of Tyr 4 and Ile 5 in the two conformations of Ang III are given in Table 13A, together with 
the theoretical values for adjacent amino acids involved in a β turn (Table 14). 
 
Except for the ψ angle of lle 5, the torsion angles in both conformations were quite 
similar and in agreement with theoretical values for a type II β turn. It should be noted that a 
fairly wide deviation from these theoretical torsion angles is permitted (± 40 o). The deviation 
observed with lle 5 cannot be explained. Figure 18B also shows the presence of interactions 





Table 13. Phi (φ) and psi (ψ) angles for Ang III (A) and IV (B).   
(A) 
 φ (Tyr) ψ (Tyr) φ (Ile) ψ (Ile) 
Angiotensin III -107.78 o 71.39 o 74.81 o 163.86 o
 
(B) 
 φ (Ile) ψ (Ile) φ (His) ψ (His) 
Angiotensin IV -134.96 o 89.94 o 80.59 o -58.19 o
 
Table 14. Theoretical values for a type I and type II β- turn.  
 φ 2 ψ 2 φ 3 ψ 3
Type I β- turn -60 o -30 o -90 o 0 o
Type II β- turn -60 o 120 o 90 o 0 o
φ2     = phi angle of the second amino acid residues involved in the turn. 
ψ2   = psi angle of the second amino acid residues involved in the turn. 
φ3  = phi angle of the third amino acid residues involved in the turn.   
ψ3  = psi angle of the third amino acid residues involved in the turn.   
 
 
  Ang IV was also built with a type II β- turn at Tyr 4, Ile 5, His 6, Pro 7 based on CD data 
and ROE connectivities. Upon minimisation and molecular dynamics, only one average 
conformation was identified (Figure 18C). This conformation was characterised by a turn 
involving Tyr 4, Ile 5, His 6 and Pro 7. The φ and ψ torsion angles of Ile 5 and His 6 are given in 
Table 13B.  As before, a deviation from theoretical values was noted for the ψ angle of the 3rd 
amino acid residue involved in the turn (namely ψ of His 6 in Ang IV).  Interactions between the 
aromatic rings of His 6 and Phe 8 were also evident from the minimised structure.  
 
 In conclusion, CD, NMR and molecular modelling (minimisation and molecular 
dynamics) were used to investigate the solution conformation of the angiotensin peptides. Based 
on these techniques, the predominant conformation of DAA-I was deduced to be that of an open 
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chain. In contrast, the predominant conformations of Ang III and Ang IV incorporated a β-turn 












Des-Asp – angiotensin I 
Ile 5 CγH - Phe 8 NH  
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(         ) showed the close proximity between two amino acid residues identified by the software Accelrys ViewerLite ®. 
 
(C-I) Angiotensin IV 
 4.3.2 Determination of Physicochemical and Size Parameters of the Angiotensin Peptides 
 
 The size parameters of the peptides were determined from the low energy average 
conformations derived from minimisation and molecular dynamics. Volume, surface area and 
polar surface area were calculated from these conformations using Insight II.  Where there were 
two low energy conformations, determinations were made for both conformations. The size 
parameters are presented in Table 15. 
 
Table 15. Polar surface area, non- polar surface area, surface area and volume of DAA-I, Ang III and Ang IV. 
 
 Polar Surface 
Area/ Å2
Non- Polar Surface 
Area/ Å2
Surface Area/ Å2 Volume/ Å3
DAA-I (Figure 17 A-I)  









Ang III (Figure 17 B-I) 









Ang IV (Figure 17 C-I) 304.42 765.22 1069.64 852.83 
 
 
 The number of possible hydrogen bonds in each peptide was determined using the method 
of Stein which involved identifying hydrogen bond donor and acceptor groups and assigning “N” 
values to them. For example, Stein assigned N = 2 to an alcoholic OH group because it can 
function as both hydrogen bond donor and acceptor. Thus, there will be 2 hydrogen bonds 
associated with the OH group. Similarly, N = 2 for an amide bond CO-NH because of the acceptor 
property of the carbonyl oxygen (N= 1) and the donor property of NH (N= 1). Werner and 
coworkers 12 have used this method to predict the number of hydrogen bonds associated with TRH 
related peptides. Using Stein’s method, the number of hydrogen bonds associated with DAA-I, 
Ang III and Ang IV were estimated to be 26, 21 and 17 respectively (Table 17). Some of these 
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hydrogen bonds were intermolecular while the rest were intramolecular. The number of 
intramolecular hydrogen bonds was determined by applying the “Measure – H bond” option 
available in Insight II ® to the minimised average conformation of each peptide. Table 16 
summarises the intramolecular hydrogen bonds that were detected in DAA-I, Ang III and Ang IV 
and the functional groups involved. Where there were two possible conformations of the peptide 
(as in the case of DAA-I and Ang III), the number of intramolecular hydrogen bonds were 
separately assessed, and the average was taken. In this way, it was found that DAA-I formed an 
average of 3 intramolecular hydrogen bonds, 3.5 intramolecular hydrogen bonds were assigned to 
Ang III and only 1 to Ang IV.  
 
Table 16. Intramolecular hydrogen bonds in DAA-I, Ang III and Ang IV. 
Peptide Conformation I Conformation II 
side chain N (Arg 2) - side chain OH (Tyr 4) side chain NH2 (Arg 2) - C=O (Val 3) a
C=O (Val 3) - NH (Ile 5)  C=O (Val 3) - NH (Ile 5) a
C=O (His 6) - NH (Phe 8) C=O (His 6) - NH (Phe 8) b
DAA-I (A) 
C=O (Pro 7) - NH (His 9) side chain OH (Tyr 4) - C=O (His 6) b
Total: 4 2 
   
terminal NH2 – terminal COOH terminal NH2 – terminal COOH 
C=O (Arg 2) – NH (Phe 8) C=O (His 6) – NH (Phe 8) c
NH (Tyr 4) – C=O (His 6) side chain NH2 (Arg 
2) – C=O (His 6) c
Ang III (B) 
C=O (Tyr 4) – NH (His 6) C=O (Tyr 4) – NH (His 6) 
Total: 4 3 
   
Ang IV (C) C=O (Tyr 4) – NH (His 6)  
Total: 1  
 
a. Insight II showed that C=O of Val 3 can be hydrogen bonded to both NH2 of Arg 
2 and lle 5.  Stein assigned N=1 to 
C=O indicating that it can only form 1 H bond although it has two lone pairs of electrons on oxygen.  Therefore, the 
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C=O of Val 3 can be either hydrogen bonded to the side chain NH2 of Arg 
2 or NH of lle 5, not to both of them at the 
same time. 
b.  C=O of His 6 can form a hydrogen bond to NH of Phe 8 or side chain OH of Tyr 4 but only one is selected. 
c. C=O of His 6 can form a hydrogen bond to NH of Phe 8 or side chain NH2 of Arg 
2 but only one is selected. 
 
 
 Subtracting the number of intramolecular hydrogen bonds from the total number of 
hydrogen bonds gives the number of intermolecular hydrogen bonds which each peptide can form. 
It is seen that hydrogen bonding potential was highest in DAA-I (23) followed by Ang III (18.5) 
and least in Ang IV (16) (Table 17).   
 
Table 17. Hydrogen bonding potential of DAA-I, Ang III and Ang IV. 
 Total number of  Hydrogen- 
Bonds 
Number of Intramolecular 
Hydrogen Bonds 
Number of Intermolecular 
Hydrogen Bonds 
DAA-I  26 3 23 
Ang III 21 3.5 18.5 
Ang IV 17 1 16 
 
 
 The lipophilicity of the peptides was determined experimentally as well as theoretically. 
Experimentally, lipophilicity was determined from the capacity factors (log Kw, pH 7.4) of the 
peptide while ClogP provided a theoretical assessment. As seen from Table 18, all 3 peptides had 
positive log kw values, indicating their lipophilic character. Lipophilicity increased in the order 
DAA-I > Ang IV > Ang III.  Theoretical ClogP values were determined in the absence of solvent 
and were not expected to be numerically comparable to log Kw values which were determined (by 
graphical extrapolation) at pH 7.4.  The ClogP of DAA-I could not be determined but those of 
Ang III and Ang IV were obtainable.  Ang IV was more lipophilic than Ang III, in keeping with 




Table 18. Physicochemical properties of angiotensin peptides. 
 Log Kw CLogP Net charge at 7.4 a pI b Molecular 
Weight 
DAA-I  3.61 N.A. + 8.76 1181.4 
Ang III 3.07 -4.10 + 8.75 931.1 
Ang IV 3.49 -2.10 0  6.71 774.9 
 
a. Ionisation states at pH 7.4 were calculated using information from 
(http://www.proteinchemist.com/chemistry/aminotable.html).  
b. pI values were obtained from (http://www.up.univ-mrs.fr/~wabim/d_abim/compo-p.html).  
    
The isoelectric point (pI) of a peptide is the pH at which the peptide has equal number of 
positive and negative charges. The peptide is neutral at its isoelectric point. The pI of DAA-I, Ang 
III and Ang IV were estimated to be 8.76, 8.75 and 6.71 respectively. Therefore, at pH 7.4, DAA-I 
and Ang III are positively charged while Ang IV is neutral. The positive charge in DAA-I and Ang 
III is due to the presence of the strongly basic guanidine group in Arg 2 of these peptides. Arginine 
is absent from Ang IV which explains why it is neutral.  
 
4.3.3 Structure- transport correlations of angiotensin peptides  
 
 DAA-I was the most lipophilic member of the three angiotensin peptides. Transcellular 
diffusion across cell membrane is analogous to a partitioning process and the lipophilic character 
of DAA-I predisposes it to this process. However, transcellular diffusion is also dependent on the 
hydrogen- bonding potential of the solute. A solute which is lipophilic (as measured by its 
partition coefficient) but has high hydrogen- bonding potential will not be as permeable as a solute 
of equivalent lipophilicity but with less hydrogen bonding potential. In this investigation, 
hydrogen bonding potential was assessed by two methods: Stein’s method of counting the number 
of hydrogen bonds (after correcting for intramolecular hydrogen bonding) and determination of 
polar surface area. Both methods have been used as surrogate markers of hydrogen- bonding, not 
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withstanding their limitations. 12, 70, 77 In this instance, there was a good correlation between 
number of hydrogen bonds and polar surface area (r2 = 0.954). Both methods assigned the highest 
hydrogen- bonding potential to DAA-I (largest polar surface area, largest count of intermolecular 
hydrogen bonds). Therefore, DAA-I had two contrasting properties that would influence 
transcellular diffusion – its favourable lipophilicity and its potential for hydrogen- bonding which 
would hinder the process. Transport experiments showed that DAA-I had rather low permeability 
across the Caco-2 cell monolayers (Papp APÆBL ≈ 10 –9 cm/sec), a possible outcome of these 
opposing trends. The transport of DAA-I showed some but not all the characteristics of a 
transcellular diffusion process. The process was temperature- independent, did not show 
directional transport and was unaffected by metabolic inhibitors, all of which are characteristic 
features of passive diffusion.  But the expected increase in flux with concentration was not 
observed.   
 
 The predominant conformation of DAA-1 in solution was deduced to be that of an open 
chain. In one study, hydrophobic tetra- and pentapeptides with significant β-turn secondary 
structures were found to transverse the Caco-2 cell monolayers by a transcellular route. The 
authors proposed that this conformational characteristic confers greater lipophilicity to the peptide, 
thus predisposing them to this route of transport. 67 It is notable that DAA-I is the only peptide 
among the three angiotensin peptides that lacked a predominant secondary structure and also the 
only one to demonstrate most of the characteristics of transcellular diffusion. This is contrary to 
the findings cited earlier. On the other hand, other investigators have shown that the formation of a 
β- turn may be induced when the peptide approaches the surface of the cell membrane, even in the 
case of peptides that have random conformations. 67,74,75 Therefore if β-turns are important for 
transcellular transport, DAA-I may actually be advantageously placed since it is not predisposed 
towards a predominant secondary structure.  
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The physicochemical characteristics of Ang III and Ang IV offered some interesting 
comparisons. Both are shorter in length than DAA-I and have smaller volumes and surface areas.  
Linear regression of molecular weight (x-axis) and volume (y-axis) showed a good correlation 
between these two parameters but the correlation between molecular weight and surface area was 
less favourable, in that the hexapeptide Ang IV appeared to have a larger surface area than would 
be expected from its molecular weight. Surface area and volume parameters were generally well 
correlated to lipophilicity. Thus, the greater lipophilicity of Ang IV (seen from its log Kw and 
ClogP values) compared to Ang III was in keeping with the larger surface area assigned to it. 
However, it raised the question as to why a shorter peptide (Ang IV) should be more lipophilic 
than a longer peptide (Ang III). Several possibilities may account for this observation. The loss of 
arginine (a basic and polar amino acid) from Ang IV may contribute to its greater lipophilicity. 
The loss of arginine reduces the pI of Ang IV, making it neutral at pH 7.4. In contrast, Ang III 
which has an arginine residue is positively charged. Since the presence of β turns in a peptide has 
been associated with greater lipophilicity, 67 the solution conformations of Ang III and Ang IV 
may offer some insight as to why lipophilicities of these peptides are different. The solution 
conformations of Ang III and Ang IV were characterised by secondary structures with β- turns. 
Open conformations were likely to be present as well. But Ang IV appeared to have fewer 
conformational options compared to Ang III. Only one low energy average conformation was 
detected for Ang IV from molecular modelling, compared to two for Ang III. The CD spectra of 
Ang IV pointed to a type II β- turn consistently from pH 3- 7.4, as compared to a mix of types I 
and II β- turns for Ang III over the same pH range. Therefore the presence of a predominant 
secondary structure (type II β- turn) in Ang IV may contribute to its lipophilic character while Ang 
III which had more conformational options was less lipophilic.  
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The transport of Ang IV across the Caco-2 cell monolayers did not have the characteristics 
of transcellular diffusion. It differed in this respect from DAA-I (most characteristics point to 
transcellular diffusion) and Ang III (more than one route implicated, one of which may be 
transcellular diffusion at high concentrations). Actually, Ang IV had several characteristics that 
should prompt its passage by transcellular diffusion: it was reasonably lipophilic (log Kw of 
DAA-I > Ang IV > Ang III), had the smallest polar surface area and lowest hydrogen bonding 
potential (DAA-I > Ang III > Ang IV). Moreover, a characteristic β- turn conformation appeared 
to be dominant, a feature that may contribute to lipophilic character and thus, transcellular 
transport.   Contrary to these expectations, the transport of Ang IV had several characteristics of an 
energy dependent process, in that it was strongly directional, reduced at low temperatures with 
loss of directional character (APÆBL ≈ BLÆAP), not affected by the metabolic inhibitor 2,4-
dinitrophenol, loss of directional character in the presence of sodium azide (another metabolic 
inhibitor) and colchicine. The present results did not permit a definite conclusion that Ang IV 
permeates cells by an energy requiring process, but the characteristics observed indicated that 
transcellular diffusion of Ang IV was highly improbable.  
 
Based on the preceding discussion, a comparison between Ang IV (which should be 
transported transcellularly but is not) and DAA-I (not optimised for transcellular transport but is 
transported in that way) was inevitable. One difference between the two peptides that had become 
apparent from this investigation relates to their solution conformations – namely the relative 
conformational flexibility of DAA-I compared to the restricted conformational options (type II β 
turn) of Ang IV.     
 
The transport characteristics of Ang III were more complicated in that more than one route 
is implicated. At high concentrations (> 10 nM), transcellular diffusion was likely (no directional 
 94
character, no temperature dependence). At lower concentrations (> 1 nM), active transport was 
involved (directional, temperature dependent, slowed down by metabolic inhibitors 2,4-
dinitrophenol and sodium azide with loss of directional transport). One may hypothesise that Ang 
III had characteristics of both DAA-I and Ang IV and this predisposed it both a non-energy 
requiring (like DAA-1) and an energy requiring (like Ang IV) route.  Some caution should be 
exercised with respect to the latter because it is not known if the same energy requiring route 
operates for Ang III and Ang IV.   
 
With respect to similarities between DAA-I and Ang III, one can cite their positively 
charged character and similar intramolecular hydrogen bonding potential. But these factors do not 
promote passive diffusion per se.  Some similarities were noted with respect to their 
conformations in that both peptides had more conformational options.  DAA-I had a random 
conformation while Ang III, not withstanding evidence pointing to a secondary structure, had 




 The present findings suggest that there is a relationship between conformation, 












 The relationship between lipophilicity and transport mode is well established. Lipophilic 
compounds are more likely to be transported transcellularly and excluded from paracellular routes.  
The relationship between conformation and lipophilicity has not been explored to a great extent in 
the literature but one investigation cited the presence of β-turns in peptides as an important factor 
in promoting lipophilicity, which in turn predisposed the peptide to the transcellular route of 
transport. Thus the connection between the three parameters is sequential (conformation Æ 
lipophilicity Æ transport mode) and the relationship between conformation and transport mode is 
indirect.  The present investigation gives further insight into the relationships among these three 
parameters. 
(i) Lipophilicity and transport mode:  DAA-I is the most lipophilic of the three peptides and it is 
characterised by a transport mode which closely resembles transcellular diffusion.  In contrast, the 
transport modes of Ang III and Ang IV are not directly connected to their lipophilicities. In 
particular, the apparent absence of a diffusion pathway for the more lipophilic Ang IV is 
unexpected. 
 
ii) Conformation and lipophilicity:  There is some support for the earlier report by Knipp et al 67 
that the presence of β turns in a peptide predisposes it to greater lipophilicity, as seen from Ang IV 
which has a predominant secondary structure (type II β turn), and is also more lipophilic than the 
longer peptide Ang III. Noting that the less lipophilic Ang III has more conformational options 
(including types I and II β turns), it appears that the presence of a predominant secondary structure 
rather than the availability of several conformational options is an important determinant of 
lipophilic character.  
 
iii) Conformation and transport mode: The observations made with Ang IV and DAA-I tentatively 
points to a direct connection between conformation and transport mode. Ang IV is transported by 
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a route that has most of the features of an energy requiring carrier- mediated process. Yet its 
physicochemical properties (lipophilicity and hydrogen bonding potential) and shape (secondary 
structure with β turn) would suggest that Ang IV is more suited for transcellular diffusion than an 
energy requiring process. On the other hand, DAA-I which does not have “optimal” features for 
transcellular transport (namely, no secondary structure and high level hydrogen bonding potential) 
is transferred almost exclusively across the Caco-2 cell monolayers by transcellular diffusion.  
There is an apparent connection between conformational flexibility and transport mode, at least for 
this series of angiotensin peptides.  At the risk of oversimplifying a complicated issue, it would 
seem that a peptide with fewer conformational options (like Ang IV) is precluded from 
transcellular diffusion transport, while a peptide with more flexibility (DAA-I, Ang III) has a 









5.  CONCLUSION 
 
 The aims of this thesis are two fold, namely, to investigate the transport properties of the 
angiotensin peptides and to determine if their transport properties are related to the 
physicochemical and size properties of the peptides. The hypothesis is that the peptides will 
display different transport properties across the Caco-2 cell monolayers, in keeping with changes 
in their size, lipophilicity, charge and conformation.   
 
 The transport of the angiotensin peptides across the Caco-2 cell monolayers share several 
similar features. All the peptides have poor permeability across the Caco-2 cell monolayers. They 
are stable to non-enzymatic hydrolysis as well as degradation by enzymes on the surface of the 
Caco-2 cell monolayers. Only DAA-I is susceptible to enzymatic degradation but the extent of 
breakdown is not excessive (≈ 30% breakdown). Thus their poor permeability is not due to 
metabolic instability. The peptides are also not substrates of Pgp (an advantage for oral 
bioavailability) and are not transported by the paracellular route. 
 
 Differences are observed in their transport routes across the Caco-2 cell monolayers. The 
transport of DAA-I shows many (but not all) characteristics of transcellular diffusion. Ang III 
demonstrates a mix of transcellular diffusion and an active transport- like process, depending on 
the concentration investigated. In the case of Ang IV, transcellular diffusion is clearly absent and 
an active transport-like process (may not be similar to that observed for Ang III) is in operation.  
Again, the classification of transport routes is not clear- cut because certain characteristics of these 
processes are not observed. 
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 Several differences in physicochemical and size properties are observed among the three 
peptides. Some of these variations can be traced to differences in the length and amino acid 
sequence of these peptides. For example, the volume of the peptides is well correlated to their 
molecular weight. The presence of arginine in DAA-I and Ang III is responsible for their similar 
pI values and positive charge at pH 7.4. The net hydrogen- bonding potential of the peptide is also 
related to the number and type of amino acids present and the observed sequence for 
intermolecular hydrogen bonding potential DAA-I > Ang III > Ang IV is in keeping with this 
trend. However, there are other physicochemical properties that are not well explained in this way, 
of which lipophilicity is a notable example. The presence of β- turns in peptides has been shown to 
be related to greater lipophilicity. 78, 79, 80 Thus, a connection between solution conformation and 
lipophilicities of the angiotensin peptides is explored.  The collective data from CD, 1H-NMR and 
molecular modelling point to greater conformational flexibility for DAA-I and Ang III as 
compared to Ang IV. The greater lipophilicity of Ang IV may be explained in part by its 
conformational characteristics.   
 
 As to whether the differences in transport properties are in any way related to differences 
in physicochemical and size properties of the peptides, there is guarded support in this direction. 
The lipophilic character of DAA-I readily explains its transcellular route of transport. For the other 
peptides, the correlation is less obvious.  One interesting observation is that transcellular diffusion 
is associated with peptides that have greater conformational flexibility. Thus, DAA-I (random 
open structure) and Ang III (more conformational flexibility compared to Ang IV) are associated 
with transcellular diffusion. On the other hand, Ang IV which has less conformational flexibility 





















































A. HPLC chromatogram of the purification of DAA-I 
B. ESI-MS spectrum used to verify the purity of the peptide. 
 














0 20 40 60 80 100 120









































































0 50 100 150 200 250 300 350































0 50 100 150 200 250 300 350






















Table 1. TEER values before and after the transport studies. 
 
Table 1A. Transepithelial electrical resistance at 37 oC. 
 
 TEER before Experiment (± SE) (Ω cm2) TEER after Experiment (± SE) (Ω cm2) 
Transport of Lucifer Yellow 302 ± 13  272 ± 10 
   
Transport of DAA-I (1 mM) 320 ± 18  298 ± 14 
Transport of DAA-I (10 µM) 158 ± 8  217 ± 12 
Transport of DAA-I (1 µM) 253 ± 10  282 ± 13 
   
Transport of Ang III (1 mM) 322 ± 19 276 ± 14 
Transport of Ang III (1 µM) 320 ± 76 203 ± 60 
Transport of Ang III (0.1 µM) 201 ± 20 192 ± 6 
Transport of Ang III (10 nM) 163 ± 8 185 ± 10 
Transport of Ang III (1 nM) 183 ± 8 207 ± 8 
   
Transport of Ang IV (1 mM) 214 ± 13 185 ± 8 
Transport of Ang IV (1 µM) 213 ± 10 256 ± 19 
Transport of Ang IV (0.1 µM) 317 ± 51 251 ± 16 
Transport of Ang IV (10 nM) 251 ± 25 293 ± 25 




Table 1B. Transepithelial electrical resistance at 4 oC and in the presence of inhibitors. 
 
 TEER before Experiment (± SE) (Ωcm2) TEER after Experiment (± SE) (Ω cm2) 
Transport of DAA-I (1 mM) (4 oC) 603 ± 45  407 ± 29 
Transport of DAA-I (1 µM) (4 oC) 471 ± 28  273 ± 12 
Transport of DAA-I (1 µM)  
(+ 0.5 mM 2,4-dinitrophenol) 
519 ± 48 396 ± 38 
Transport of DAA-I (1 µM)  
(+ 1 µM colchicine) 434 ± 49 359 ± 35 
Transport of DAA-I (1 µM) 
(+ 25 mM sodium azide) 
408 ± 51 333 ± 38 
Transport of DAA-I (1 µM) 
(+ 1.25 mM EDTA) 
361 ± 38 256 ± 39 
   
Transport of Ang III (1 mM) (4 oC) 651 ± 87 595 ± 95 
Transport of Ang III (1 nM) (4 oC) 466 ± 29  311 ± 23 
Transport of Ang III (1 nM)  
(+ 0.5 mM 2,4-dinitrophenol) 
415 ± 50 321 ± 27 
Transport of Ang III (1 nM)  
(+ 1 µM colchicine) 339 ± 54 302 ± 30 
Transport of Ang III (1 nM) 
(+ 25 mM sodium azide) 
349 ± 21 293 ± 2 
Transport of Ang III (1 nM) 
(+ 1.25 mM EDTA) 
416 ± 31 320 ± 35 
   
Transport of Ang IV (1 mM) (4 oC) 630 ± 13  375 ± 4 
Transport of Ang IV (1 nM) (4 oC) 425 ± 24 330 ± 15 
Transport of Ang IV (1 nM)  
(+ 0.5 mM 2,4-dinitrophenol) 
490 ± 57 448 ± 59 
Transport of Ang IV (1 nM)  
(+ 1 µM colchicine) 244 ± 10 286 ± 6 
Transport of Ang IV (1 nM) 
(+ 25 mM sodium azide) 
375 ± 68 230 ± 24 
 AV
Transport of Ang IV (1 nM) 
(+ 1.25 mM EDTA) 




Figure 4. Separation and analysis of angiotensin peptides. 
 

































































































































The amount of non- radiolabelled peptides transported across the Caco-2 cell monolayers was quantified by HPLC in 
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